<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Antivirals: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int391-antivirals.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int391-antivirals.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="bnf_int391-antivirals.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 13 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int390-zuclopenthixol.htm" title="Previous: Zuclopenthixol">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int1225-rilpivirine.htm" title="Next: Rilpivirine">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="pB"><?highlighter on?><h1>Antivirals</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><p><strong>Antivirals</strong> has no specific interaction information.</p><p><strong>Rilpivirine</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>manufacturer of </span><span>rilpivirine</span> <span>advises give</span> <span>antacids</span> <span>2 hours before or 4 hours after <span>rilpivirine</span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int465-calcium-salts.htm">Calcium Salts</a></td><td><p><span>manufacturer of </span><span>rilpivirine</span> <span>advises give</span> <span>calcium salts</span> <span>2 hours before or 4 hours after <span>rilpivirine</span></span></p></td><td><div class="cG"><p><strong>Note:</strong> <em>see also</em> Antacids</p></div></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>manufacturer of </span><span>rilpivirine</span> <span>advises avoid concomitant use with</span> <span>carbamazepine</span> <span>(plasma concentration of <span>rilpivirine</span> possibly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>manufacturer of </span><span>rilpivirine</span> <span>advises avoid concomitant use with</span> <span>clarithromycin</span> <span>(plasma concentration of <span>rilpivirine</span> possibly increased)</span></p></td><td></td></tr><tr><td><a href="bnf_int1120-dabigatran-etexilate.htm">Dabigatran Etexilate</a></td><td><p><span></span> <span>rilpivirine</span> <span>possibly increases plasma concentration of</span> <span>dabigatran etexilate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int490-dexamethasone.htm">Dexamethasone</a></td><td class="cAI"><p><span>manufacturer of </span><span>rilpivirine</span> <span>advises avoid concomitant use with</span> <span>dexamethasone</span> <span>(except when given as a single dose)</span></p></td><td></td></tr><tr><td><a href="bnf_int397-didanosine.htm">Didanosine</a></td><td><p><span>manufacturer of </span><span>rilpivirine</span> <span>advises give</span> <span>didanosine</span> <span>2 hours before or 4 hours after <span>rilpivirine</span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids in tablet formulation may affect absorption of other drugs</p></div></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>rilpivirine</span> <span>possibly increases plasma concentration of</span> <span>digoxin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>manufacturer of </span><span>rilpivirine</span> <span>advises avoid concomitant use with</span> <span>erythromycin</span> <span>(plasma concentration of <span>rilpivirine</span> possibly increased)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int914-esomeprazole.htm">Esomeprazole</a></td><td><p><span>manufacturer of </span><span>rilpivirine</span> <span>advises avoid concomitant use with</span> <span>esomeprazole</span> <span>(plasma concentration of <span>rilpivirine</span> possibly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int743-histamine-h-2-antagonists.htm">Histamine H<sub>2</sub>-antagonists</a></td><td><p><span>manufacturer of </span><span>rilpivirine</span> <span>advises avoid</span> <span>histamine H<sub>2</sub>-antagonists</span> <span>for 12 hours before or 4 hours after <span>rilpivirine</span>—consult product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int753-lansoprazole.htm">Lansoprazole</a></td><td><p><span>manufacturer of </span><span>rilpivirine</span> <span>advises avoid concomitant use with</span> <span>lansoprazole</span> <span>(plasma concentration of <span>rilpivirine</span> possibly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int267-metformin.htm">Metformin</a></td><td><p><span></span> <span>rilpivirine</span> <span>possibly increases plasma concentration of</span> <span>metformin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>rilpivirine</span> <span>possibly reduces plasma concentration of</span> <span>methadone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int752-omeprazole.htm">Omeprazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>rilpivirine</span> <span>reduced by</span> <span>omeprazole</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int900-oxcarbazepine.htm">Oxcarbazepine</a></td><td class="cAI"><p><span>manufacturer of </span><span>rilpivirine</span> <span>advises avoid concomitant use with</span> <span>oxcarbazepine</span> <span>(plasma concentration of <span>rilpivirine</span> possibly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int754-pantoprazole.htm">Pantoprazole</a></td><td><p><span>manufacturer of </span><span>rilpivirine</span> <span>advises avoid concomitant use with</span> <span>pantoprazole</span> <span>(plasma concentration of <span>rilpivirine</span> possibly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span>manufacturer of </span><span>rilpivirine</span> <span>advises avoid concomitant use with</span> <span>phenobarbital</span> <span>(plasma concentration of <span>rilpivirine</span> possibly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>manufacturer of </span><span>rilpivirine</span> <span>advises avoid concomitant use with</span> <span>phenytoin</span> <span>(plasma concentration of <span>rilpivirine</span> possibly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int869-rabeprazole.htm">Rabeprazole</a></td><td><p><span>manufacturer of </span><span>rilpivirine</span> <span>advises avoid concomitant use with</span> <span>rabeprazole</span> <span>(plasma concentration of <span>rilpivirine</span> possibly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>rilpivirine</span> <span>reduced by</span> <span>rifabutin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>rilpivirine</span> <span>reduced by</span> <span>rifampicin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>manufacturer of </span><span>rilpivirine</span> <span>advises avoid concomitant use with</span> <span>St John's wort</span> <span>(plasma concentration of <span>rilpivirine</span> possibly reduced)</span></p></td><td></td></tr></tbody></table><p><strong>Telaprevir</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int30-alfuzosin.htm">Alfuzosin</a></td><td class="cAI"><p><span>manufacturer of </span><span>telaprevir</span> <span>advises avoid concomitant use with</span> <span>alfuzosin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>manufacturer of </span><span>telaprevir</span> <span>advises avoid concomitant use with</span> <span>amiodarone</span> <span>(risk of ventricular arrhythmias)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int470-amlodipine.htm">Amlodipine</a></td><td><p><span></span> <span>telaprevir</span> <span>increases plasma concentration of</span> <span>amlodipine</span> <span>(consider reducing dose of <span>amlodipine</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int1217-apixaban.htm">Apixaban</a></td><td><p><span>avoidance of </span><span>telaprevir</span> <span>advised by manufacturer of</span> <span>apixaban</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td><p><span>plasma concentration of </span><span>telaprevir</span> <span>possibly reduced by</span> <span>atazanavir</span><span>, also plasma concentration of <span>atazanavir</span> possibly increased</span></p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td class="cAI"><p><span>manufacturer of </span><span>telaprevir</span> <span>advises avoid concomitant use with</span> <span>atorvastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int943-bosentan.htm">Bosentan</a></td><td><p><span>plasma concentration of </span><span>telaprevir</span> <span>possibly reduced by</span> <span>bosentan</span><span>, also plasma concentration of <span>bosentan</span> possibly increased</span></p></td><td></td></tr><tr><td><a href="bnf_int496-budesonide.htm">Budesonide</a></td><td><p><span></span> <span>telaprevir</span> <span>possibly increases plasma concentration of <em>inhaled</em> and <em>intranasal</em></span> <span>budesonide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>manufacturer of </span><span>telaprevir</span> <span>advises avoid concomitant use with</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>plasma concentration of both drugs increased when </span><span>telaprevir</span> <span>given with</span> <span>ciclosporin</span> <span>(reduce dose of <span>ciclosporin</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>plasma concentration of both drugs possibly increased when </span><span>telaprevir</span> <span>given with</span> <span>clarithromycin</span> <span>(increased risk of ventricular arrhythmias)</span></p></td><td></td></tr><tr><td><a href="bnf_int483-colchicine.htm">Colchicine</a></td><td class="cAI"><p><span></span> <span>telaprevir</span> <span>possibly increases risk of</span> <span>colchicine</span> <span>toxicity—suspend or reduce dose of <span>colchicine</span> (avoid concomitant use in hepatic or renal impairment)</span></p></td><td></td></tr><tr><td><a href="bnf_int1120-dabigatran-etexilate.htm">Dabigatran Etexilate</a></td><td><p><span></span> <span>telaprevir</span> <span>possibly increases plasma concentration of</span> <span>dabigatran etexilate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td class="cAI"><p><span>avoid concomitant use of </span><span>telaprevir</span> <span>with</span> <span>darunavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int490-dexamethasone.htm">Dexamethasone</a></td><td><p><span>plasma concentration of </span><span>telaprevir</span> <span>possibly reduced by</span> <span>dexamethasone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>telaprevir</span> <span>increases plasma concentration of</span> <span>digoxin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int468-diltiazem.htm">Diltiazem</a></td><td><p><span>manufacturer of </span><span>telaprevir</span> <span>advises caution with</span> <span>diltiazem</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>manufacturer of </span><span>telaprevir</span> <span>advises avoid concomitant use with</span> <span>disopyramide</span> <span>(risk of ventricular arrhythmias)</span></p></td><td></td></tr><tr><td><a href="bnf_int553-domperidone.htm">Domperidone</a></td><td class="cAI"><p><span></span> <span>telaprevir</span> <span>possibly increases plasma concentration of </span><span>domperidone</span><span>—manufacturer of <span>telaprevir</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td class="cAI"><p><span>plasma concentration of </span><span>telaprevir</span> <span>reduced by</span> <span>efavirenz</span><span>—increase dose of <span>telaprevir</span></span></p></td><td></td></tr><tr><td><a href="bnf_int981-ergot-alkaloids.htm">Ergot Alkaloids</a></td><td class="cAI"><p><span>manufacturer of </span><span>telaprevir</span> <span>advises avoid concomitant use with</span> <span>ergot alkaloids</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>plasma concentration of both drugs possibly increased when </span><span>telaprevir</span> <span>given with</span> <span>erythromycin</span> <span>(increased risk of ventricular arrhythmias)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int638-ethinylestradiol.htm">Ethinylestradiol</a></td><td class="cAI"><p><span></span> <span>telaprevir</span> <span>possibly reduces plasma concentration of</span> <span>ethinylestradiol</span><span>—manufacturer of <span>telaprevir</span> advises additional contraceptive precautions</span></p></td><td></td></tr><tr><td><a href="bnf_int471-felodipine.htm">Felodipine</a></td><td><p><span>manufacturer of </span><span>telaprevir</span> <span>advises caution with</span> <span>felodipine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int120-flecainide.htm">Flecainide</a></td><td class="cAI"><p><span>manufacturer of </span><span>telaprevir</span> <span>advises caution with</span> <span>flecainide</span> <span>(risk of ventricular arrhythmias)</span></p></td><td></td></tr><tr><td><a href="bnf_int497-fluticasone.htm">Fluticasone</a></td><td><p><span></span> <span>telaprevir</span> <span>possibly increases plasma concentration of <em>inhaled</em> and <em>intranasal</em></span> <span>fluticasone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span>manufacturers advise avoid concomitant use of </span><span>telaprevir</span> <span>with</span> <span>fosamprenavir</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span></span> <span>telaprevir</span> <span>possibly increases plasma concentration of</span> <span>itraconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>plasma concentration of both drugs possibly increased when </span><span>telaprevir</span> <span>given with</span> <span>ketoconazole</span> <span>(increased risk of ventricular arrhythmias)</span></p></td><td></td></tr><tr><td><a href="bnf_int55-lidocaine.htm">Lidocaine</a></td><td><p><span>manufacturer of </span><span>telaprevir</span> <span>advises caution with <em>intravenous</em></span> <span>lidocaine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions less likely when lidocaine used topically</p></div></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td class="cAI"><p><span>manufacturers advise avoid concomitant use of </span><span>telaprevir</span> <span>with</span> <span>lopinavir</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as <em>Kaletra</em>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td class="cAI"><p><span>manufacturer of </span><span>telaprevir</span> <span>advises caution with</span> <span>methadone</span> <span>(risk of ventricular arrhythmias)</span></p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td class="cAI"><p><span></span> <span>telaprevir</span> <span>possibly increases plasma concentration of</span> <span>midazolam</span> <span>(risk of prolonged sedation—avoid concomitant use of <em>oral</em><span>midazolam</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int474-nicardipine.htm">Nicardipine</a></td><td><p><span>manufacturer of </span><span>telaprevir</span> <span>advises caution with</span> <span>nicardipine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int475-nifedipine.htm">Nifedipine</a></td><td><p><span>manufacturer of </span><span>telaprevir</span> <span>advises caution with</span> <span>nifedipine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span>manufacturer of </span><span>telaprevir</span> <span>advises avoid concomitant use with</span> <span>phenobarbital</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>manufacturer of </span><span>telaprevir</span> <span>advises avoid concomitant use with</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>manufacturer of </span><span>telaprevir</span> <span>advises avoid concomitant use with</span> <span>pimozide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span></span> <span>telaprevir</span> <span>possibly increases plasma concentration of</span> <span>posaconazole</span> <span>(increased risk of ventricular arrhythmias)</span></p></td><td></td></tr><tr><td><a href="bnf_int125-propafenone.htm">Propafenone</a></td><td class="cAI"><p><span>manufacturer of </span><span>telaprevir</span> <span>advises caution with</span> <span>propafenone</span> <span>(risk of ventricular arrhythmias)</span></p></td><td></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td class="cAI"><p><span></span> <span>telaprevir</span> <span>possibly increases plasma concentration of</span> <span>quetiapine</span><span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span>manufacturer of </span><span>telaprevir</span> <span>advises avoid concomitant use with</span> <span>rifabutin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>telaprevir</span> <span>significantly reduced by</span> <span>rifampicin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span><span>telaprevir</span> <span>possibly reduced by</span> <span>ritonavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1231-ruxolitinib.htm">Ruxolitinib</a></td><td class="cAI"><p><span>manufacturer of <span>ruxolitinib</span> advises dose reduction when </span><span>telaprevir</span> <span>given with</span> <span>ruxolitinib</span><span>—consult <span>ruxolitinib</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int727-salmeterol.htm">Salmeterol</a></td><td class="cAI"><p><span>manufacturer of </span><span>telaprevir</span> <span>advises avoid concomitant use with</span> <span>salmeterol</span> <span>(risk of ventricular arrhythmias)</span></p></td><td></td></tr><tr><td><a href="bnf_int858-sildenafil.htm">Sildenafil</a></td><td class="cAI"><p><span>manufacturer of </span><span>telaprevir</span> <span>advises avoid concomitant use with</span> <span>sildenafil</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>manufacturers advise avoid concomitant use of </span><span>telaprevir</span> <span>with</span> <span>simvastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td class="cAI"><p><span>plasma concentration of both drugs increased when </span><span>telaprevir</span> <span>given with</span> <span>sirolimus</span> <span>(reduce dose of <span>sirolimus</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int455-sotalol.htm">Sotalol</a></td><td class="cAI"><p><span>manufacturer of </span><span>telaprevir</span> <span>advises avoid concomitant use with</span> <span>sotalol</span> <span>(risk of ventricular arrhythmias)</span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>manufacturer of </span><span>telaprevir</span> <span>advises avoid concomitant use with</span> <span>St John's wort</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span>plasma concentration of both drugs increased when </span><span>telaprevir</span> <span>given with</span> <span>tacrolimus</span> <span>(reduce dose of <span>tacrolimus</span>)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int945-tadalafil.htm">Tadalafil</a></td><td class="cAI"><p><span>manufacturer of </span><span>telaprevir</span> <span>advises avoid concomitant use with high doses of</span> <span>tadalafil</span><span>—consult product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>plasma concentration of both drugs possibly increased when </span><span>telaprevir</span> <span>given with</span> <span>telithromycin</span> <span>(increased risk of ventricular arrhythmias)</span></p></td><td></td></tr><tr><td><a href="bnf_int954-tenofovir.htm">Tenofovir</a></td><td><p><span></span> <span>telaprevir</span> <span>increases plasma concentration of</span> <span>tenofovir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int255-trazodone.htm">Trazodone</a></td><td><p><span></span> <span>telaprevir</span> <span>possibly increases plasma concentration of</span> <span>trazodone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int967-vardenafil.htm">Vardenafil</a></td><td class="cAI"><p><span>manufacturer of </span><span>telaprevir</span> <span>advises avoid concomitant use with</span> <span>vardenafil</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td><p><span>manufacturer of </span><span>telaprevir</span> <span>advises caution with</span> <span>verapamil</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span></span> <span>telaprevir</span> <span>possibly affects plasma concentration of</span> <span>voriconazole</span> <span>(possible increased risk of ventricular arrhythmias)</span></p></td><td></td></tr><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td class="cAI"><p><span></span> <span>telaprevir</span> <span>possibly affects plasma concentration of</span> <span>warfarin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Boceprevir</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1217-apixaban.htm">Apixaban</a></td><td><p><span>avoidance of </span><span>boceprevir</span> <span>advised by manufacturer of</span> <span>apixaban</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td class="cAI"><p><span>manufacturer of </span><span>boceprevir</span> <span>advises avoid concomitant use with</span> <span>artemether with lumefantrine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span></span> <span>boceprevir</span> <span>reduces plasma concentration of</span> <span>atazanavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td class="cAI"><p><span></span> <span>boceprevir</span> <span>enhances effects and increases toxicity of</span> <span>atorvastatin</span> <span>(reduce dose of <span>atorvastatin</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>manufacturer of </span><span>boceprevir</span> <span>advises avoid concomitant use with</span> <span>carbamazepine</span> <span>(plasma concentration of <span>boceprevir</span> possibly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>boceprevir</span> <span>increases plasma concentration of</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td class="cAI"><p><span>avoid concomitant use of </span><span>boceprevir</span> <span>with</span> <span>darunavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1077-dasatinib.htm">Dasatinib</a></td><td class="cAI"><p><span>manufacturer of </span><span>boceprevir</span> <span>advises avoid concomitant use with</span> <span>dasatinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int962-drospirenone.htm">Drospirenone</a></td><td><p><span></span> <span>boceprevir</span> <span>increases plasma concentration of</span> <span>drospirenone</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int981-ergot-alkaloids.htm">Ergot Alkaloids</a></td><td class="cAI"><p><span>manufacturer of </span><span>boceprevir</span> <span>advises avoid concomitant use with</span> <span>ergot alkaloids</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1048-erlotinib.htm">Erlotinib</a></td><td class="cAI"><p><span>manufacturer of </span><span>boceprevir</span> <span>advises avoid concomitant use with</span> <span>erlotinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span>avoidance of </span><span>boceprevir</span> <span>advised by manufacturer of</span> <span>fosamprenavir</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int1170-gefitinib.htm">Gefitinib</a></td><td class="cAI"><p><span>manufacturer of </span><span>boceprevir</span> <span>advises avoid concomitant use with</span> <span>gefitinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int933-imatinib.htm">Imatinib</a></td><td class="cAI"><p><span>manufacturer of </span><span>boceprevir</span> <span>advises avoid concomitant use with</span> <span>imatinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>boceprevir</span> <span>increased by</span> <span>ketoconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td class="cAI"><p><span>manufacturer of </span><span>boceprevir</span> <span>advises avoid concomitant use with</span> <span>lapatinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td class="cAI"><p><span>manufacturers advise avoid concomitant use of </span><span>boceprevir</span> <span>with</span> <span>lopinavir</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as <em>Kaletra</em>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>boceprevir</span> <span>possibly affects plasma concentration of</span> <span>methadone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td class="cAI"><p><span></span> <span>boceprevir</span> <span>increases plasma concentration of <em>oral</em></span> <span>midazolam</span><span>—manufacturer of <span>boceprevir</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1118-nilotinib.htm">Nilotinib</a></td><td class="cAI"><p><span>manufacturer of </span><span>boceprevir</span> <span>advises avoid concomitant use with</span> <span>nilotinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td class="cAI"><p><span></span> <span>boceprevir</span> <span>possibly causes contraceptive failure of hormonal contraceptives containing</span> <span>oestrogens</span> <span>(alternative contraception recommended)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int1186-pazopanib.htm">Pazopanib</a></td><td class="cAI"><p><span>manufacturer of </span><span>boceprevir</span> <span>advises avoid concomitant use with</span> <span>pazopanib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span>manufacturer of </span><span>boceprevir</span> <span>advises avoid concomitant use with</span> <span>phenobarbital</span> <span>(plasma concentration of <span>boceprevir</span> possibly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>manufacturer of </span><span>boceprevir</span> <span>advises avoid concomitant use with</span> <span>phenytoin</span> <span>(plasma concentration of <span>boceprevir</span> possibly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>manufacturer of </span><span>boceprevir</span> <span>advises avoid concomitant use with</span> <span>pimozide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int604-pravastatin.htm">Pravastatin</a></td><td><p><span></span> <span>boceprevir</span> <span>increases plasma concentration of</span> <span>pravastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td class="cAI"><p><span></span> <span>boceprevir</span> <span>possibly increases plasma concentration of</span> <span>quetiapine</span><span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>manufacturer of </span><span>boceprevir</span> <span>advises avoid concomitant use with</span> <span>rifampicin</span> <span>(plasma concentration of <span>boceprevir</span> possibly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of both drugs reduced when </span><span>boceprevir</span> <span>given with</span> <span>ritonavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1231-ruxolitinib.htm">Ruxolitinib</a></td><td class="cAI"><p><span>manufacturer of <span>ruxolitinib</span> advises dose reduction when </span><span>boceprevir</span> <span>given with</span> <span>ruxolitinib</span><span>—consult <span>ruxolitinib</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>manufacturers advise avoid concomitant use of </span><span>boceprevir</span> <span>with</span> <span>simvastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td class="cAI"><p><span></span> <span>boceprevir</span> <span>possibly increases plasma concentration of</span> <span>sirolimus</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1074-sorafenib.htm">Sorafenib</a></td><td class="cAI"><p><span>manufacturer of </span><span>boceprevir</span> <span>advises avoid concomitant use with</span> <span>sorafenib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1075-sunitinib.htm">Sunitinib</a></td><td class="cAI"><p><span>manufacturer of </span><span>boceprevir</span> <span>advises avoid concomitant use with</span> <span>sunitinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>boceprevir</span> <span>increases plasma concentration of</span> <span>tacrolimus</span> <span>(reduce dose of <span>tacrolimus</span>)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr></tbody></table><p><strong>Etravirine</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td><p><span></span> <span>etravirine</span> <span>possibly reduces plasma concentration of</span> <span>atorvastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>manufacturer of </span><span>etravirine</span> <span>advises avoid concomitant use with</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>etravirine</span> <span>increased by</span> <span>clarithromycin</span><span>, also plasma concentration of <span>clarithromycin</span> reduced</span></p></td><td></td></tr><tr><td><a href="bnf_int865-clopidogrel.htm">Clopidogrel</a></td><td class="cAI"><p><span></span> <span>etravirine</span> <span>possibly reduces antiplatelet effect of</span> <span>clopidogrel</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>etravirine</span> <span>increases plasma concentration of</span> <span>digoxin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td class="cAI"><p><span>plasma concentration of </span><span>etravirine</span> <span>possibly reduced by</span> <span>efavirenz</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span></span> <span>etravirine</span> <span>increases plasma concentration of</span> <span>fosamprenavir</span> <span>(consider reducing dose of <span>fosamprenavir</span>)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span></span> <span>etravirine</span> <span>possibly reduces plasma concentration of</span> <span>indinavir</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1107-maraviroc.htm">Maraviroc</a></td><td><p><span></span> <span>etravirine</span> <span>possibly reduces plasma concentration of</span> <span>maraviroc</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td class="cAI"><p><span>plasma concentration of </span><span>etravirine</span> <span>possibly reduced by</span> <span>nevirapine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>manufacturer of </span><span>etravirine</span> <span>advises avoid concomitant use with</span> <span>phenobarbital</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>manufacturer of </span><span>etravirine</span> <span>advises avoid concomitant use with</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span>plasma concentration of both drugs reduced when </span><span>etravirine</span> <span>given with</span> <span>rifabutin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>manufacturer of </span><span>etravirine</span> <span>advises avoid concomitant use with</span> <span>rifampicin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int858-sildenafil.htm">Sildenafil</a></td><td><p><span></span> <span>etravirine</span> <span>reduces plasma concentration of</span> <span>sildenafil</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td><p><span>manufacturer of </span><span>etravirine</span> <span>advises avoid concomitant use with</span> <span>St John's wort</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>etravirine</span> <span>reduced by</span> <span>tipranavir</span><span>, also plasma concentration of <span>tipranavir</span> increased (avoid concomitant use)</span></p></td><td></td></tr></tbody></table><p><strong>Fosamprenavir</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span></span> <span>fosamprenavir</span> <span>possibly increases plasma concentration of</span> <span>amiodarone</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int1217-apixaban.htm">Apixaban</a></td><td><p><span>avoidance of </span><span>fosamprenavir</span> <span>advised by manufacturer of</span> <span>apixaban</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>fosamprenavir</span> <span>possibly inhibits metabolism of</span> <span>aripiprazole</span> <span>(reduce dose of <span>aripiprazole</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td><p><span>caution with </span><span>fosamprenavir</span> <span>advised by manufacturer of</span> <span>artemether with lumefantrine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td><p><span>possible increased risk of myopathy when </span><span>fosamprenavir</span> <span>given with</span> <span>atorvastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>manufacturer of </span><span>fosamprenavir</span> <span>advises avoid concomitant use with</span> <span>boceprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span><span>fosamprenavir</span> <span>possibly reduced by</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>fosamprenavir</span> <span>increases plasma concentration of</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td><p><span></span> <span>fosamprenavir</span> <span>may enhance or reduce anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int1076-darifenacin.htm">Darifenacin</a></td><td><p><span>avoidance of </span><span>fosamprenavir</span> <span>advised by manufacturer of</span> <span>darifenacin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int563-ergotamine-and-methysergide.htm">Ergotamine and Methysergide</a></td><td class="cAI"><p><span>increased risk of ergotism when </span><span>fosamprenavir</span> <span>given with</span> <span>ergotamine and methysergide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1135-etravirine.htm">Etravirine</a></td><td class="cAI"><p><span>plasma concentration of </span><span>fosamprenavir</span> <span>increased by</span> <span>etravirine</span> <span>(consider reducing dose of <span>fosamprenavir</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int120-flecainide.htm">Flecainide</a></td><td class="cAI"><p><span></span> <span>fosamprenavir</span> <span>possibly increases plasma concentration of</span> <span>flecainide</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span>plasma concentration of both drugs may increase when </span><span>fosamprenavir</span> <span>given with</span> <span>itraconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td><p><span></span> <span>fosamprenavir</span> <span>increases plasma concentration of</span> <span>ketoconazole</span> <span>(also plasma concentration of <span>fosamprenavir</span> possibly increased)</span></p></td><td></td></tr><tr><td><a href="bnf_int55-lidocaine.htm">Lidocaine</a></td><td class="cAI"><p><span></span> <span>fosamprenavir</span> <span>possibly increases plasma concentration of</span> <span>lidocaine</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions less likely when lidocaine used topically</p></div></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td><p><span>plasma concentration of </span><span>fosamprenavir</span> <span>reduced by</span> <span>lopinavir</span><span>, effect on <span>lopinavir</span> plasma concentration not predictable—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as <em>Kaletra</em>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>fosamprenavir</span> <span>reduces plasma concentration of</span> <span>methadone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td class="cAI"><p><span></span> <span>fosamprenavir</span> <span>possibly increases plasma concentration of</span> <span>midazolam</span> <span>(risk of prolonged sedation—avoid concomitant use of <em>oral</em><span>midazolam</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td><p><span>plasma concentration of </span><span>fosamprenavir</span> <span>possibly reduced by</span> <span>nevirapine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span><span>fosamprenavir</span> <span>possibly reduced by</span> <span>phenobarbital</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span></span> <span>fosamprenavir</span> <span>increases plasma concentration of</span> <span>pimozide</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td><p><span></span> <span>fosamprenavir</span> <span>possibly reduces plasma concentration of</span> <span>posaconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int125-propafenone.htm">Propafenone</a></td><td class="cAI"><p><span></span> <span>fosamprenavir</span> <span>possibly increases plasma concentration of</span> <span>propafenone</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td class="cAI"><p><span></span> <span>fosamprenavir</span> <span>possibly increases plasma concentration of</span> <span>quetiapine</span><span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int341-quinine.htm">Quinine</a></td><td class="cAI"><p><span></span> <span>fosamprenavir</span> <span>possibly increases plasma concentration of</span> <span>quinine</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int1111-raltegravir.htm">Raltegravir</a></td><td class="cAI"><p><span>manufacturer of </span><span>fosamprenavir</span> <span>advises avoid concomitant use with</span> <span>raltegravir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td class="cAI"><p><span></span> <span>fosamprenavir</span> <span>possibly increases plasma concentration of</span> <span>ranolazine</span><span>—manufacturer of <span>ranolazine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span></span> <span>fosamprenavir</span> <span>increases plasma concentration of</span> <span>rifabutin</span> <span>(reduce dose of <span>rifabutin</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>fosamprenavir</span> <span>significantly reduced by</span> <span>rifampicin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1136-rivaroxaban.htm">Rivaroxaban</a></td><td><p><span>avoidance of </span><span>fosamprenavir</span> <span>advised by manufacturer of</span> <span>rivaroxaban</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int974-rosuvastatin.htm">Rosuvastatin</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>fosamprenavir</span> <span>given with</span> <span>rosuvastatin</span><span>—manufacturer of <span>rosuvastatin</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int858-sildenafil.htm">Sildenafil</a></td><td><p><span></span> <span>fosamprenavir</span> <span>possibly increases plasma concentration of</span> <span>sildenafil</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>fosamprenavir</span> <span>given with</span> <span>simvastatin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span><span>fosamprenavir</span> <span>reduced by</span> <span>St John's wort</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>fosamprenavir</span> <span>increases plasma concentration of</span> <span>tacrolimus</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int945-tadalafil.htm">Tadalafil</a></td><td><p><span></span> <span>fosamprenavir</span> <span>possibly increases plasma concentration of</span> <span>tadalafil</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>manufacturers advise avoid concomitant use of </span><span>fosamprenavir</span> <span>with</span> <span>telaprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>avoidance of concomitant </span><span>fosamprenavir</span> <span>in severe renal and hepatic impairment advised by manufacturer of</span> <span>telithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>fosamprenavir</span> <span>reduced by</span> <span>tipranavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int850-tolterodine.htm">Tolterodine</a></td><td><p><span>avoidance of </span><span>fosamprenavir</span> <span>advised by manufacturer of</span> <span>tolterodine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int967-vardenafil.htm">Vardenafil</a></td><td><p><span></span> <span>fosamprenavir</span> <span>possibly increases plasma concentration of</span> <span>vardenafil</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Telbivudine</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int586-interferon-alfa.htm">Interferon Alfa</a></td><td class="cAI"><p><span>increased risk of peripheral neuropathy when </span><span>telbivudine</span> <span>given with</span> <span>interferon alfa</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Raltegravir</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span>avoidance of </span><span>raltegravir</span> <span>advised by manufacturer of</span> <span>fosamprenavir</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int743-histamine-h-2-antagonists.htm">Histamine H<sub>2</sub>-antagonists</a></td><td><p><span>plasma concentration of </span><span>raltegravir</span> <span>possibly increased by</span> <span>histamine H<sub>2</sub>-antagonists</span><span>—manufacturer of <span>raltegravir</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int752-omeprazole.htm">Omeprazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>raltegravir</span> <span>increased by</span> <span>omeprazole</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int751-proton-pump-inhibitors.htm">Proton Pump Inhibitors</a></td><td><p><span>plasma concentration of </span><span>raltegravir</span> <span>possibly increased by</span> <span>proton pump inhibitors</span><span>—manufacturer of <span>raltegravir</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>raltegravir</span> <span>reduced by</span> <span>rifampicin</span><span>—consider increasing dose of <span>raltegravir</span></span></p></td><td></td></tr></tbody></table><p><strong>Maraviroc</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>maraviroc</span> <span>increased by</span> <span>atazanavir</span> <span>(consider reducing dose of <span>maraviroc</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>maraviroc</span> <span>possibly increased by</span> <span>clarithromycin</span> <span>(consider reducing dose of <span>maraviroc</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>maraviroc</span> <span>increased by</span> <span>darunavir</span> <span>(consider reducing dose of <span>maraviroc</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td class="cAI"><p><span>plasma concentration of </span><span>maraviroc</span> <span>possibly reduced by</span> <span>efavirenz</span><span>—consider increasing dose of <span>maraviroc</span></span></p></td><td></td></tr><tr><td><a href="bnf_int1135-etravirine.htm">Etravirine</a></td><td><p><span>plasma concentration of </span><span>maraviroc</span> <span>possibly reduced by</span> <span>etravirine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>maraviroc</span> <span>increased by</span> <span>indinavir</span> <span>(consider reducing dose of <span>maraviroc</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>maraviroc</span> <span>increased by</span> <span>ketoconazole</span> <span>(consider reducing dose of <span>maraviroc</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>maraviroc</span> <span>increased by</span> <span>lopinavir</span> <span>(consider reducing dose of <span>maraviroc</span>)</span></p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as <em>Kaletra</em>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>maraviroc</span> <span>reduced by</span> <span>rifampicin</span><span>—consider increasing dose of <span>maraviroc</span></span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span><span>maraviroc</span> <span>increased by</span> <span>ritonavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>maraviroc</span> <span>increased by</span> <span>saquinavir</span> <span>(consider reducing dose of <span>maraviroc</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span><span>maraviroc</span> <span>possibly reduced by</span> <span>St John's wort</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>maraviroc</span> <span>possibly increased by</span> <span>telithromycin</span> <span>(consider reducing dose of <span>maraviroc</span>)</span></p></td><td></td></tr></tbody></table><p><strong>Darunavir</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1217-apixaban.htm">Apixaban</a></td><td><p><span>avoidance of </span><span>darunavir</span> <span>advised by manufacturer of</span> <span>apixaban</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td><p><span>possible increased risk of myopathy when </span><span>darunavir</span> <span>given with</span> <span>atorvastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoid concomitant use of </span><span>darunavir</span> <span>with</span> <span>boceprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span><span>darunavir</span> <span>possibly reduced by</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td class="cAI"><p><span>Plasma concentration of </span><span>darunavir</span> <span>reduced by</span> <span>efavirenz</span> <span>(adjust dose—consult product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int1169-everolimus.htm">Everolimus</a></td><td class="cAI"><p><span></span> <span>darunavir</span> <span>possibly increases plasma concentration of</span> <span>everolimus</span><span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td><p><span>plasma concentration of both drugs increased when </span><span>darunavir</span> <span>given with</span> <span>indinavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td><p><span>plasma concentration of both drugs increased when </span><span>darunavir</span> <span>given with</span> <span>ketoconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int55-lidocaine.htm">Lidocaine</a></td><td><p><span></span> <span>darunavir</span> <span>possibly increases plasma concentration of</span> <span>lidocaine</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions less likely when lidocaine used topically</p></div></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>darunavir</span> <span>reduced by</span> <span>lopinavir</span><span>, also plasma concentration of <span>lopinavir</span> increased (avoid concomitant use)</span></p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as <em>Kaletra</em>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int985-lumefantrine.htm">Lumefantrine</a></td><td><p><span></span> <span>darunavir</span> <span>increases plasma concentration of</span> <span>lumefantrine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Lumefantrine interactions as for artemether with lumefantrine</p></div></td></tr><tr><td><a href="bnf_int1107-maraviroc.htm">Maraviroc</a></td><td class="cAI"><p><span></span> <span>darunavir</span> <span>increases plasma concentration of</span> <span>maraviroc</span> <span>(consider reducing dose of <span>maraviroc</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int236-paroxetine.htm">Paroxetine</a></td><td><p><span></span> <span>darunavir</span> <span>possibly reduces plasma concentration of</span> <span>paroxetine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span><span>darunavir</span> <span>possibly reduced by</span> <span>phenobarbital</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span><span>darunavir</span> <span>possibly reduced by</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int604-pravastatin.htm">Pravastatin</a></td><td><p><span></span> <span>darunavir</span> <span>possibly increases plasma concentration of</span> <span>pravastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td class="cAI"><p><span></span> <span>darunavir</span> <span>possibly increases plasma concentration of</span> <span>quetiapine</span><span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int341-quinine.htm">Quinine</a></td><td class="cAI"><p><span></span> <span>darunavir</span> <span>possibly increases plasma concentration of</span> <span>quinine</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td class="cAI"><p><span></span> <span>darunavir</span> <span>possibly increases plasma concentration of</span> <span>ranolazine</span><span>—manufacturer of <span>ranolazine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span></span> <span>darunavir</span> <span>increases plasma concentration of</span> <span>rifabutin</span> <span>(reduce dose of <span>rifabutin</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>darunavir</span> <span>significantly reduced by</span> <span>rifampicin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1136-rivaroxaban.htm">Rivaroxaban</a></td><td><p><span>avoidance of </span><span>darunavir</span> <span>advised by manufacturer of</span> <span>rivaroxaban</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int974-rosuvastatin.htm">Rosuvastatin</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>darunavir</span> <span>given with</span> <span>rosuvastatin</span><span>—manufacturer of <span>rosuvastatin</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td><p><span>plasma concentration of </span><span>darunavir</span> <span>reduced by</span> <span>saquinavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int237-sertraline.htm">Sertraline</a></td><td><p><span></span> <span>darunavir</span> <span>possibly reduces plasma concentration of</span> <span>sertraline</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span><span>darunavir</span> <span>reduced by</span> <span>St John's wort</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>avoid concomitant use of </span><span>darunavir</span> <span>with</span> <span>telaprevir</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Adefovir</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int959-peginterferon-alfa.htm">Peginterferon Alfa</a></td><td><p><span>manufacturer of </span><span>adefovir</span> <span>advises caution with</span> <span>peginterferon alfa</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Peginterferon alfa interactions as for interferon alfa</p></div></td></tr><tr><td><a href="bnf_int954-tenofovir.htm">Tenofovir</a></td><td><p><span>avoidance of </span><span>adefovir</span> <span>advised by manufacturer of</span> <span>tenofovir</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Tipranavir</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int907-abacavir.htm">Abacavir</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>reduces plasma concentration of</span> <span>abacavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span><span>tipranavir</span> <span>reduced by</span> <span>antacids</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int1217-apixaban.htm">Apixaban</a></td><td><p><span>avoidance of </span><span>tipranavir</span> <span>advised by manufacturer of</span> <span>apixaban</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td><p><span>caution with </span><span>tipranavir</span> <span>advised by manufacturer of</span> <span>artemether with lumefantrine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td><p><span>plasma concentration of </span><span>tipranavir</span> <span>increased by</span> <span>atazanavir</span> <span>(also plasma concentration of <span>atazanavir</span> reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>tipranavir</span> <span>given with</span> <span>atorvastatin</span> <span>(see Dose under Atorvastatin, <a title="ATORVASTATIN (Monograph)" href="PHP1633-atorvastatin.htm">section 2.12</a>)</span></p></td><td></td></tr><tr><td><a href="bnf_int943-bosentan.htm">Bosentan</a></td><td><p><span>manufacturer of </span><span>tipranavir</span> <span>advises avoid concomitant use with</span> <span>bosentan</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int87-buprenorphine.htm">Buprenorphine</a></td><td><p><span>plasma concentration of </span><span>tipranavir</span> <span>possibly reduced by</span> <span>buprenorphine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span><span>tipranavir</span> <span>possibly reduced by</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>increases plasma concentration of</span> <span>clarithromycin</span> <span>(reduce dose of <span>clarithromycin</span> in renal impairment), also plasma concentration of <span>tipranavir</span> increased by <span>clarithromycin</span></span></p></td><td></td></tr><tr><td><a href="bnf_int1076-darifenacin.htm">Darifenacin</a></td><td><p><span>avoidance of </span><span>tipranavir</span> <span>advised by manufacturer of</span> <span>darifenacin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int397-didanosine.htm">Didanosine</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>reduces plasma concentration of</span> <span>didanosine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids in tablet formulation may affect absorption of other drugs</p></div></td></tr><tr><td><a href="bnf_int914-esomeprazole.htm">Esomeprazole</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>reduces plasma concentration of</span> <span>esomeprazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1135-etravirine.htm">Etravirine</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>reduces plasma concentration of</span> <span>etravirine</span><span>, also plasma concentration of <span>tipranavir</span> increased (avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td><p><span>plasma concentration of </span><span>tipranavir</span> <span>increased by</span> <span>fluconazole</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>reduces plasma concentration of</span> <span>fosamprenavir</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>reduces plasma concentration of</span> <span>lopinavir</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as <em>Kaletra</em>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int451-metoprolol.htm">Metoprolol</a></td><td class="cAI"><p><span>manufacturer of </span><span>tipranavir</span> <span>advises avoid concomitant use with</span> <span>metoprolol</span> <span>for heart failure</span></p></td><td></td></tr><tr><td><a href="bnf_int752-omeprazole.htm">Omeprazole</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>reduces plasma concentration of</span> <span>omeprazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>possibly increases plasma concentration of</span> <span>quetiapine</span><span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int341-quinine.htm">Quinine</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>possibly increases plasma concentration of</span> <span>quinine</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>possibly increases plasma concentration of</span> <span>ranolazine</span><span>—manufacturer of <span>ranolazine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>increases plasma concentration of</span> <span>rifabutin</span> <span>(reduce dose of <span>rifabutin</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>tipranavir</span> <span>possibly reduced by</span> <span>rifampicin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1136-rivaroxaban.htm">Rivaroxaban</a></td><td><p><span>avoidance of </span><span>tipranavir</span> <span>advised by manufacturer of</span> <span>rivaroxaban</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int974-rosuvastatin.htm">Rosuvastatin</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>possibly increases plasma concentration of</span> <span>rosuvastatin</span><span>—manufacturer of <span>rosuvastatin</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int727-salmeterol.htm">Salmeterol</a></td><td><p><span>manufacturer of </span><span>tipranavir</span> <span>advises avoid concomitant use with</span> <span>salmeterol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>reduces plasma concentration of</span> <span>saquinavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>possibly increases plasma concentration of</span> <span>simvastatin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span><span>tipranavir</span> <span>possibly reduced by</span> <span>St John's wort</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>avoidance of concomitant </span><span>tipranavir</span> <span>in severe renal and hepatic impairment advised by manufacturer of</span> <span>telithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int967-vardenafil.htm">Vardenafil</a></td><td><p><span>manufacturer of </span><span>tipranavir</span> <span>advises caution with</span> <span>vardenafil</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1134-vitamin-e.htm">Vitamin E</a></td><td><p><span>increased risk of bleeding when </span><span>tipranavir</span> <span>given with high doses of</span> <span>vitamin E</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int403-zidovudine.htm">Zidovudine</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>reduces plasma concentration of</span> <span>zidovudine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</p></div></td></tr></tbody></table><p><strong>Atazanavir</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span></span> <span>atazanavir</span> <span>possibly increases plasma concentration of</span> <span>amiodarone</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>plasma concentration of </span><span>atazanavir</span> <span>possibly reduced by</span> <span>antacids</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int1217-apixaban.htm">Apixaban</a></td><td><p><span>avoidance of </span><span>atazanavir</span> <span>advised by manufacturer of</span> <span>apixaban</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>atazanavir</span> <span>possibly inhibits metabolism of</span> <span>aripiprazole</span> <span>(reduce dose of <span>aripiprazole</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td><p><span>caution with </span><span>atazanavir</span> <span>advised by manufacturer of</span> <span>artemether with lumefantrine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>atazanavir</span> <span>given with</span> <span>atorvastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1235-axitinib.htm">Axitinib</a></td><td><p><span></span> <span>atazanavir</span> <span>possibly increases plasma concentration of</span> <span>axitinib</span> <span>(reduce dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>atazanavir</span> <span>reduced by</span> <span>boceprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1204-cabazitaxel.htm">Cabazitaxel</a></td><td class="cAI"><p><span>avoidance of </span><span>atazanavir</span> <span>advised by manufacturer of</span> <span>cabazitaxel</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>atazanavir</span> <span>possibly increases plasma concentration of</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td><p><span>plasma concentration of both drugs increased when </span><span>atazanavir</span> <span>given with</span> <span>clarithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int483-colchicine.htm">Colchicine</a></td><td class="cAI"><p><span></span> <span>atazanavir</span> <span>possibly increases risk of</span> <span>colchicine</span> <span>toxicity—suspend or reduce dose of <span>colchicine</span> (avoid concomitant use in hepatic or renal impairment)</span></p></td><td></td></tr><tr><td><a href="bnf_int1240-crizotinib.htm">Crizotinib</a></td><td class="cAI"><p><span></span> <span>atazanavir</span> <span>possibly increases plasma concentration of</span> <span>crizotinib</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1076-darifenacin.htm">Darifenacin</a></td><td><p><span>avoidance of </span><span>atazanavir</span> <span>advised by manufacturer of</span> <span>darifenacin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int468-diltiazem.htm">Diltiazem</a></td><td class="cAI"><p><span></span> <span>atazanavir</span> <span>increases plasma concentration of</span> <span>diltiazem</span> <span>(reduce dose of <span>diltiazem</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td class="cAI"><p><span>manufacturer of </span><span>atazanavir</span> <span>advises avoid concomitant use with</span> <span>efavirenz</span> <span>(plasma concentration of <span>atazanavir</span> reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int981-ergot-alkaloids.htm">Ergot Alkaloids</a></td><td class="cAI"><p><span></span> <span>atazanavir</span> <span>possibly increases plasma concentration of</span> <span>ergot alkaloids</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int638-ethinylestradiol.htm">Ethinylestradiol</a></td><td><p><span></span> <span>atazanavir</span> <span>increases plasma concentration of</span> <span>ethinylestradiol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1169-everolimus.htm">Everolimus</a></td><td class="cAI"><p><span></span> <span>atazanavir</span> <span>possibly increases plasma concentration of</span> <span>everolimus</span><span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1119-fesoterodine.htm">Fesoterodine</a></td><td><p><span>manufacturer of <span>fesoterodine</span> advises dose reduction when </span><span>atazanavir</span> <span>given with</span> <span>fesoterodine</span><span>—consult <span>fesoterodine</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int743-histamine-h-2-antagonists.htm">Histamine H<sub>2</sub>-antagonists</a></td><td class="cAI"><p><span>plasma concentration of </span><span>atazanavir</span> <span>reduced by</span> <span>histamine H<sub>2</sub>-antagonists</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>avoid concomitant use of </span><span>atazanavir</span> <span>with</span> <span>indinavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1006-irinotecan.htm">Irinotecan</a></td><td class="cAI"><p><span></span> <span>atazanavir</span> <span>possibly inhibits metabolism of</span> <span>irinotecan</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int55-lidocaine.htm">Lidocaine</a></td><td class="cAI"><p><span></span> <span>atazanavir</span> <span>possibly increases plasma concentration of</span> <span>lidocaine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions less likely when lidocaine used topically</p></div></td></tr><tr><td><a href="bnf_int1107-maraviroc.htm">Maraviroc</a></td><td class="cAI"><p><span></span> <span>atazanavir</span> <span>increases plasma concentration of</span> <span>maraviroc</span> <span>(consider reducing dose of <span>maraviroc</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td class="cAI"><p><span></span> <span>atazanavir</span> <span>possibly increases plasma concentration of</span> <span>midazolam</span><span>—avoid concomitant use of <em>oral</em><span>midazolam</span></span></p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td class="cAI"><p><span>plasma concentration of </span><span>atazanavir</span> <span>possibly reduced by</span> <span>nevirapine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int673-norethisterone.htm">Norethisterone</a></td><td><p><span></span> <span>atazanavir</span> <span>increases plasma concentration of</span> <span>norethisterone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1186-pazopanib.htm">Pazopanib</a></td><td class="cAI"><p><span>avoidance of </span><span>atazanavir</span> <span>advised by manufacturer of</span> <span>pazopanib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span></span> <span>atazanavir</span> <span>possibly increases plasma concentration of</span> <span>pimozide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>atazanavir</span> <span>increased by</span> <span>posaconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int604-pravastatin.htm">Pravastatin</a></td><td><p><span>possible increased risk of myopathy when </span><span>atazanavir</span> <span>given with</span> <span>pravastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int751-proton-pump-inhibitors.htm">Proton Pump Inhibitors</a></td><td class="cAI"><p><span>plasma concentration of </span><span>atazanavir</span> <span>reduced by</span> <span>proton pump inhibitors</span><span>—avoid or adjust dose of both drugs (consult product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td class="cAI"><p><span></span> <span>atazanavir</span> <span>possibly increases plasma concentration of</span> <span>quetiapine</span><span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int341-quinine.htm">Quinine</a></td><td class="cAI"><p><span></span> <span>atazanavir</span> <span>possibly increases plasma concentration of</span> <span>quinine</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td class="cAI"><p><span></span> <span>atazanavir</span> <span>possibly increases plasma concentration of</span> <span>ranolazine</span><span>—manufacturer of <span>ranolazine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span></span> <span>atazanavir</span> <span>increases plasma concentration of</span> <span>rifabutin</span> <span>(reduce dose of <span>rifabutin</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>atazanavir</span> <span>reduced by</span> <span>rifampicin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1136-rivaroxaban.htm">Rivaroxaban</a></td><td><p><span>avoidance of </span><span>atazanavir</span> <span>advised by manufacturer of</span> <span>rivaroxaban</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int974-rosuvastatin.htm">Rosuvastatin</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>atazanavir</span> <span>given with</span> <span>rosuvastatin</span><span>—manufacturer of <span>rosuvastatin</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>atazanavir</span> <span>given with</span> <span>saquinavir</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int858-sildenafil.htm">Sildenafil</a></td><td class="cAI"><p><span></span> <span>atazanavir</span> <span>possibly increases side-effects of</span> <span>sildenafil</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>atazanavir</span> <span>given with</span> <span>simvastatin</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td class="cAI"><p><span></span> <span>atazanavir</span> <span>possibly increases plasma concentration of</span> <span>sirolimus</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span><span>atazanavir</span> <span>reduced by</span> <span>St John's wort</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>atazanavir</span> <span>possibly increases plasma concentration of</span> <span>tacrolimus</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td><p><span></span> <span>atazanavir</span> <span>possibly reduces plasma concentration of</span> <span>telaprevir</span><span>, also plasma concentration of <span>atazanavir</span> possibly increased</span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>avoidance of concomitant </span><span>atazanavir</span> <span>in severe renal and hepatic impairment advised by manufacturer of</span> <span>telithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int954-tenofovir.htm">Tenofovir</a></td><td><p><span>plasma concentration of </span><span>atazanavir</span> <span>reduced by</span> <span>tenofovir</span><span>, also plasma concentration of <span>tenofovir</span> possibly increased</span></p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td class="cAI"><p><span></span> <span>atazanavir</span> <span>possibly increases plasma concentration of</span> <span>ticagrelor</span><span>—manufacturer of <span>ticagrelor</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td><p><span></span> <span>atazanavir</span> <span>increases plasma concentration of</span> <span>tipranavir</span> <span>(also plasma concentration of <span>atazanavir</span> reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td><p><span></span> <span>atazanavir</span> <span>possibly increases plasma concentration of</span> <span>verapamil</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td><p><span></span> <span>atazanavir</span> <span>may enhance or reduce anticoagulant effect of</span> <span>warfarin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Emtricitabine</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int399-lamivudine.htm">Lamivudine</a></td><td><p><span>manufacturer of </span><span>emtricitabine</span> <span>advises avoid concomitant use with</span> <span>lamivudine</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Tenofovir</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1088-adefovir.htm">Adefovir</a></td><td><p><span>manufacturer of </span><span>tenofovir</span> <span>advises avoid concomitant use with</span> <span>adefovir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td><p><span></span> <span>tenofovir</span> <span>reduces plasma concentration of</span> <span>atazanavir</span><span>, also plasma concentration of <span>tenofovir</span> possibly increased</span></p></td><td></td></tr><tr><td><a href="bnf_int951-cidofovir.htm">Cidofovir</a></td><td class="cAI"><p><span>manufacturers advise avoid concomitant use of </span><span>tenofovir</span> <span>with</span> <span>cidofovir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int397-didanosine.htm">Didanosine</a></td><td class="cAI"><p><span></span> <span>tenofovir</span> <span>increases plasma concentration of</span> <span>didanosine</span> <span>(increased risk of toxicity)—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids in tablet formulation may affect absorption of other drugs</p></div></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td><p><span>plasma concentration of </span><span>tenofovir</span> <span>increased by</span> <span>lopinavir</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as <em>Kaletra</em>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td><p><span>plasma concentration of </span><span>tenofovir</span> <span>increased by</span> <span>telaprevir</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Ribavirin</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int907-abacavir.htm">Abacavir</a></td><td class="cAI"><p><span>effects of </span><span>ribavirin</span> <span>possibly reduced by</span> <span>abacavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int519-azathioprine.htm">Azathioprine</a></td><td class="cAI"><p><span></span> <span>ribavirin</span> <span>possibly enhances myelosuppressive effects of</span> <span>azathioprine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int397-didanosine.htm">Didanosine</a></td><td class="cAI"><p><span>increased risk of side-effects when </span><span>ribavirin</span> <span>given with</span> <span>didanosine</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids in tablet formulation may affect absorption of other drugs</p></div></td></tr><tr><td><a href="bnf_int401-stavudine.htm">Stavudine</a></td><td class="cAI"><p><span>increased risk of toxicity when </span><span>ribavirin</span> <span>given with</span> <span>stavudine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int403-zidovudine.htm">Zidovudine</a></td><td class="cAI"><p><span>increased risk of anaemia when </span><span>ribavirin</span> <span>given with</span> <span>zidovudine</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</p></div></td></tr></tbody></table><p><strong>Foscarnet</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int808-pentamidine-isetionate.htm">Pentamidine Isetionate</a></td><td class="cAI"><p><span>increased risk of hypocalcaemia when </span><span>foscarnet</span> <span>given with <em>parenteral</em></span> <span>pentamidine isetionate</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Cidofovir</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int954-tenofovir.htm">Tenofovir</a></td><td class="cAI"><p><span>manufacturers advise avoid concomitant use of </span><span>cidofovir</span> <span>with</span> <span>tenofovir</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Abacavir</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>abacavir</span> <span>possibly reduces plasma concentration of</span> <span>methadone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span><span>abacavir</span> <span>possibly reduced by</span> <span>phenobarbital</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span><span>abacavir</span> <span>possibly reduced by</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int953-ribavirin.htm">Ribavirin</a></td><td class="cAI"><p><span></span> <span>abacavir</span> <span>possibly reduces effects of</span> <span>ribavirin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span><span>abacavir</span> <span>possibly reduced by</span> <span>rifampicin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>abacavir</span> <span>reduced by</span> <span>tipranavir</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Aciclovir</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Interactions do not apply to topical aciclovir preparations</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td><p><span>increased risk of nephrotoxicity when </span><span>aciclovir</span> <span>given with</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int520-mycophenolate.htm">Mycophenolate</a></td><td><p><span>plasma concentration of </span><span>aciclovir</span> <span>increased by</span> <span>mycophenolate</span><span>, also plasma concentration of inactive metabolite of <span>mycophenolate</span> increased</span></p></td><td></td></tr><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td><p><span>excretion of </span><span>aciclovir</span> <span>reduced by</span> <span>probenecid</span> <span>(increased plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td><p><span>possible increased risk of nephrotoxicity when </span><span>aciclovir</span> <span>given with</span> <span>tacrolimus</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td><p><span></span> <span>aciclovir</span> <span>possibly increases plasma concentration of</span> <span>theophylline</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Valaciclovir</strong> belongs to <strong>Antivirals</strong> but has no specific interaction information.</p><div class="cG"><p><strong>Note:</strong> Valaciclovir interactions as for aciclovir</p></div><p><strong>Didanosine</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Antacids in tablet formulation may affect absorption of other drugs</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int22-allopurinol.htm">Allopurinol</a></td><td class="cAI"><p><span>plasma concentration of </span><span>didanosine</span> <span>increased by</span> <span>allopurinol</span> <span>(risk of toxicity)—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int395-ganciclovir.htm">Ganciclovir</a></td><td><p><span>plasma concentration of </span><span>didanosine</span> <span>possibly increased by</span> <span>ganciclovir</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of myelosuppression with other myelosuppressive drugs—consult product literature</p></div></td></tr><tr><td><a href="bnf_int1052-hydroxycarbamide.htm">Hydroxycarbamide</a></td><td class="cAI"><p><span>increased risk of toxicity when </span><span>didanosine</span> <span>given with</span> <span>hydroxycarbamide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span>plasma concentration of </span><span>didanosine</span> <span>possibly reduced by</span> <span>methadone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int953-ribavirin.htm">Ribavirin</a></td><td class="cAI"><p><span>increased risk of side-effects when </span><span>didanosine</span> <span>given with</span> <span>ribavirin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1225-rilpivirine.htm">Rilpivirine</a></td><td><p><span>manufacturer of <span>rilpivirine</span> advises give </span><span>didanosine</span> <span>2 hours before or 4 hours after</span> <span>rilpivirine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int401-stavudine.htm">Stavudine</a></td><td class="cAI"><p><span>increased risk of side-effects when </span><span>didanosine</span> <span>given with</span> <span>stavudine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int954-tenofovir.htm">Tenofovir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>didanosine</span> <span>increased by</span> <span>tenofovir</span> <span>(increased risk of toxicity)—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>didanosine</span> <span>reduced by</span> <span>tipranavir</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Efavirenz</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>efavirenz</span> <span>possibly reduces plasma concentration of</span> <span>aripiprazole</span><span>—increase dose of <span>aripiprazole</span></span></p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>avoidance of </span><span>efavirenz</span> <span>advised by manufacturer of</span> <span>atazanavir</span> <span>(plasma concentration of <span>atazanavir</span> reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td><p><span></span> <span>efavirenz</span> <span>reduces plasma concentration of</span> <span>atorvastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int431-atovaquone.htm">Atovaquone</a></td><td class="cAI"><p><span></span> <span>efavirenz</span> <span>reduces plasma concentration of</span> <span>atovaquone</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int896-bupropion.htm">Bupropion</a></td><td><p><span></span> <span>efavirenz</span> <span>accelerates metabolism of</span> <span>bupropion</span> <span>(reduced plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of both drugs reduced when </span><span>efavirenz</span> <span>given with</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int947-caspofungin.htm">Caspofungin</a></td><td><p><span></span> <span>efavirenz</span> <span>possibly reduces plasma concentration of</span> <span>caspofungin</span><span>—consider increasing dose of <span>caspofungin</span></span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>efavirenz</span> <span>possibly reduces plasma concentration of</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td><p><span>increased risk of rash when </span><span>efavirenz</span> <span>given with</span> <span>clarithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>efavirenz</span> <span>possibly affects plasma concentration of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td class="cAI"><p><span></span> <span>efavirenz</span> <span>reduces plasma concentration of</span> <span>darunavir</span> <span>(adjust dose—consult product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int468-diltiazem.htm">Diltiazem</a></td><td><p><span></span> <span>efavirenz</span> <span>reduces plasma concentration of</span> <span>diltiazem</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int981-ergot-alkaloids.htm">Ergot Alkaloids</a></td><td class="cAI"><p><span>increased risk of ergotism when </span><span>efavirenz</span> <span>given with</span> <span>ergot alkaloids</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1135-etravirine.htm">Etravirine</a></td><td class="cAI"><p><span></span> <span>efavirenz</span> <span>possibly reduces plasma concentration of</span> <span>etravirine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td><p><span>plasma concentration of </span><span>efavirenz</span> <span>possibly increased by</span> <span>grapefruit juice</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td><p><span></span> <span>efavirenz</span> <span>reduces plasma concentration of</span> <span>indinavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span></span> <span>efavirenz</span> <span>reduces plasma concentration of</span> <span>itraconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td class="cAI"><p><span></span> <span>efavirenz</span> <span>reduces plasma concentration of</span> <span>lopinavir</span><span>—consider increasing dose of <span>lopinavir</span></span></p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as <em>Kaletra</em>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int1107-maraviroc.htm">Maraviroc</a></td><td class="cAI"><p><span></span> <span>efavirenz</span> <span>possibly reduces plasma concentration of</span> <span>maraviroc</span><span>—consider increasing dose of <span>maraviroc</span></span></p></td><td></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>efavirenz</span> <span>reduces plasma concentration of</span> <span>methadone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td class="cAI"><p><span>increased risk of prolonged sedation when </span><span>efavirenz</span> <span>given with</span> <span>midazolam</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td><p><span>plasma concentration of </span><span>efavirenz</span> <span>reduced by</span> <span>nevirapine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span></span> <span>efavirenz</span> <span>possibly increases plasma concentration of</span> <span>pimozide</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span></span> <span>efavirenz</span> <span>reduces plasma concentration of</span> <span>posaconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int604-pravastatin.htm">Pravastatin</a></td><td><p><span></span> <span>efavirenz</span> <span>reduces plasma concentration of</span> <span>pravastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td class="cAI"><p><span></span> <span>efavirenz</span> <span>possibly reduces contraceptive effect of</span> <span>progestogens</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr><tr><td><a href="bnf_int339-proguanil.htm">Proguanil</a></td><td><p><span></span> <span>efavirenz</span> <span>possibly affects plasma concentration of</span> <span>proguanil</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td><p><span></span> <span>efavirenz</span> <span>reduces plasma concentration of</span> <span>rifabutin</span><span>—increase dose of <span>rifabutin</span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span><span>efavirenz</span> <span>reduced by</span> <span>rifampicin</span><span>—increase dose of <span>efavirenz</span></span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>toxicity of </span><span>efavirenz</span> <span>increased by</span> <span>ritonavir</span><span>, monitor liver function tests</span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td><p><span></span> <span>efavirenz</span> <span>significantly reduces plasma concentration of</span> <span>saquinavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td><p><span></span> <span>efavirenz</span> <span>reduces plasma concentration of</span> <span>simvastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span><span>efavirenz</span> <span>reduced by</span> <span>St John's wort</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>efavirenz</span> <span>possibly affects plasma concentration of</span> <span>tacrolimus</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span></span> <span>efavirenz</span> <span>reduces plasma concentration of</span> <span>telaprevir</span><span>—increase dose of <span>telaprevir</span></span></p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span></span> <span>efavirenz</span> <span>reduces plasma concentration of</span> <span>voriconazole</span><span>, also plasma concentration of <span>efavirenz</span> increased (increase <span>voriconazole</span> dose and reduce <span>efavirenz</span> dose)</span></p></td><td></td></tr></tbody></table><p><strong>Famciclovir</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td><p><span>excretion of </span><span>famciclovir</span> <span>possibly reduced by</span> <span>probenecid</span> <span>(increased plasma concentration)</span></p></td><td></td></tr></tbody></table><p><strong>Ganciclovir</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Increased risk of myelosuppression with other myelosuppressive drugs—consult product literature</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int397-didanosine.htm">Didanosine</a></td><td><p><span></span> <span>ganciclovir</span> <span>possibly increases plasma concentration of</span> <span>didanosine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids in tablet formulation may affect absorption of other drugs</p></div></td></tr><tr><td><a href="bnf_int139-imipenem-with-cilastatin.htm">Imipenem with Cilastatin</a></td><td class="cAI"><p><span>increased risk of convulsions when </span><span>ganciclovir</span> <span>given with</span> <span>imipenem with cilastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int520-mycophenolate.htm">Mycophenolate</a></td><td><p><span>plasma concentration of </span><span>ganciclovir</span> <span>possibly increased by</span> <span>mycophenolate</span><span>, also plasma concentration of inactive metabolite of <span>mycophenolate</span> possibly increased</span></p></td><td></td></tr><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td><p><span>excretion of </span><span>ganciclovir</span> <span>reduced by</span> <span>probenecid</span> <span>(increased plasma concentration and risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td><p><span>possible increased risk of nephrotoxicity when </span><span>ganciclovir</span> <span>given with</span> <span>tacrolimus</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int403-zidovudine.htm">Zidovudine</a></td><td class="cAI"><p><span>profound myelosuppression when </span><span>ganciclovir</span> <span>given with</span> <span>zidovudine</span> <span>(if possible avoid concomitant administration, particularly during initial <span>ganciclovir</span> therapy)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</p></div></td></tr></tbody></table><p><strong>Valganciclovir</strong> belongs to <strong>Antivirals</strong> but has no specific interaction information.</p><div class="cG"><p><strong>Note:</strong> Valganciclovir interactions as for ganciclovir</p></div><p><strong>Indinavir</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int21-aldesleukin.htm">Aldesleukin</a></td><td><p><span>plasma concentration of </span><span>indinavir</span> <span>possibly increased by</span> <span>aldesleukin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int406-alprazolam.htm">Alprazolam</a></td><td class="cAI"><p><span>increased risk of prolonged sedation when </span><span>indinavir</span> <span>given with</span> <span>alprazolam</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span></span> <span>indinavir</span> <span>possibly increases plasma concentration of</span> <span>amiodarone</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int1217-apixaban.htm">Apixaban</a></td><td><p><span>avoidance of </span><span>indinavir</span> <span>advised by manufacturer of</span> <span>apixaban</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>indinavir</span> <span>possibly inhibits metabolism of</span> <span>aripiprazole</span> <span>(reduce dose of <span>aripiprazole</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td><p><span>caution with </span><span>indinavir</span> <span>advised by manufacturer of</span> <span>artemether with lumefantrine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>avoid concomitant use of </span><span>indinavir</span> <span>with</span> <span>atazanavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td><p><span>possible increased risk of myopathy when </span><span>indinavir</span> <span>given with</span> <span>atorvastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int431-atovaquone.htm">Atovaquone</a></td><td><p><span>plasma concentration of </span><span>indinavir</span> <span>possibly reduced by</span> <span>atovaquone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1235-axitinib.htm">Axitinib</a></td><td><p><span></span> <span>indinavir</span> <span>possibly increases plasma concentration of</span> <span>axitinib</span> <span>(reduce dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int1204-cabazitaxel.htm">Cabazitaxel</a></td><td class="cAI"><p><span>avoidance of </span><span>indinavir</span> <span>advised by manufacturer of</span> <span>cabazitaxel</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>plasma concentration of </span><span>indinavir</span> <span>possibly reduced by</span> <span>carbamazepine</span><span>, also plasma concentration of <span>carbamazepine</span> possibly increased</span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>indinavir</span> <span>increases plasma concentration of</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int483-colchicine.htm">Colchicine</a></td><td class="cAI"><p><span></span> <span>indinavir</span> <span>possibly increases risk of</span> <span>colchicine</span> <span>toxicity—suspend or reduce dose of <span>colchicine</span> (avoid concomitant use in hepatic or renal impairment)</span></p></td><td></td></tr><tr><td><a href="bnf_int1240-crizotinib.htm">Crizotinib</a></td><td class="cAI"><p><span></span> <span>indinavir</span> <span>possibly increases plasma concentration of</span> <span>crizotinib</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1076-darifenacin.htm">Darifenacin</a></td><td><p><span>avoidance of </span><span>indinavir</span> <span>advised by manufacturer of</span> <span>darifenacin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td><p><span>plasma concentration of both drugs increased when </span><span>indinavir</span> <span>given with</span> <span>darunavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int490-dexamethasone.htm">Dexamethasone</a></td><td><p><span>plasma concentration of </span><span>indinavir</span> <span>possibly reduced by</span> <span>dexamethasone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td><p><span>plasma concentration of </span><span>indinavir</span> <span>reduced by</span> <span>efavirenz</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int963-eletriptan.htm">Eletriptan</a></td><td class="cAI"><p><span></span> <span>indinavir</span> <span>increases plasma concentration of</span> <span>eletriptan</span> <span>(risk of toxicity)—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int563-ergotamine-and-methysergide.htm">Ergotamine and Methysergide</a></td><td class="cAI"><p><span>increased risk of ergotism when </span><span>indinavir</span> <span>given with</span> <span>ergotamine and methysergide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1135-etravirine.htm">Etravirine</a></td><td class="cAI"><p><span>plasma concentration of </span><span>indinavir</span> <span>possibly reduced by</span> <span>etravirine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1169-everolimus.htm">Everolimus</a></td><td class="cAI"><p><span></span> <span>indinavir</span> <span>possibly increases plasma concentration of</span> <span>everolimus</span><span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1119-fesoterodine.htm">Fesoterodine</a></td><td><p><span>manufacturer of <span>fesoterodine</span> advises dose reduction when </span><span>indinavir</span> <span>given with</span> <span>fesoterodine</span><span>—consult <span>fesoterodine</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int120-flecainide.htm">Flecainide</a></td><td class="cAI"><p><span></span> <span>indinavir</span> <span>possibly increases plasma concentration of</span> <span>flecainide</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>indinavir</span> <span>increased by</span> <span>itraconazole</span> <span>(consider reducing dose of <span>indinavir</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>indinavir</span> <span>increased by</span> <span>ketoconazole</span> <span>(consider reducing dose of <span>indinavir</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int1107-maraviroc.htm">Maraviroc</a></td><td class="cAI"><p><span></span> <span>indinavir</span> <span>increases plasma concentration of</span> <span>maraviroc</span> <span>(consider reducing dose of <span>maraviroc</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td class="cAI"><p><span></span> <span>indinavir</span> <span>possibly increases plasma concentration of</span> <span>midazolam</span> <span>(risk of prolonged sedation—avoid concomitant use of <em>oral</em><span>midazolam</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td><p><span>plasma concentration of </span><span>indinavir</span> <span>reduced by</span> <span>nevirapine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1186-pazopanib.htm">Pazopanib</a></td><td class="cAI"><p><span>avoidance of </span><span>indinavir</span> <span>advised by manufacturer of</span> <span>pazopanib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span>plasma concentration of </span><span>indinavir</span> <span>possibly reduced by</span> <span>phenobarbital</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>indinavir</span> <span>possibly reduced by</span> <span>phenytoin</span><span>, also plasma concentration of <span>phenytoin</span> possibly increased</span></p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span></span> <span>indinavir</span> <span>possibly increases plasma concentration of</span> <span>pimozide</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td class="cAI"><p><span></span> <span>indinavir</span> <span>possibly increases plasma concentration of</span> <span>quetiapine</span><span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int341-quinine.htm">Quinine</a></td><td class="cAI"><p><span></span> <span>indinavir</span> <span>possibly increases plasma concentration of</span> <span>quinine</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td class="cAI"><p><span></span> <span>indinavir</span> <span>possibly increases plasma concentration of</span> <span>ranolazine</span><span>—manufacturer of <span>ranolazine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span></span> <span>indinavir</span> <span>increases plasma concentration of</span> <span>rifabutin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>metabolism of </span><span>indinavir</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced plasma concentration—avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span><span>indinavir</span> <span>increased by</span> <span>ritonavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1136-rivaroxaban.htm">Rivaroxaban</a></td><td><p><span>avoidance of </span><span>indinavir</span> <span>advised by manufacturer of</span> <span>rivaroxaban</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int974-rosuvastatin.htm">Rosuvastatin</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>indinavir</span> <span>given with</span> <span>rosuvastatin</span><span>—manufacturer of <span>rosuvastatin</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1231-ruxolitinib.htm">Ruxolitinib</a></td><td class="cAI"><p><span>manufacturer of <span>ruxolitinib</span> advises dose reduction when </span><span>indinavir</span> <span>given with</span> <span>ruxolitinib</span><span>—consult <span>ruxolitinib</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td><p><span></span> <span>indinavir</span> <span>increases plasma concentration of</span> <span>saquinavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int858-sildenafil.htm">Sildenafil</a></td><td class="cAI"><p><span></span> <span>indinavir</span> <span>increases plasma concentration of</span> <span>sildenafil</span><span>—reduce initial dose of <span>sildenafil</span></span></p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>indinavir</span> <span>given with</span> <span>simvastatin</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span><span>indinavir</span> <span>reduced by</span> <span>St John's wort</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int945-tadalafil.htm">Tadalafil</a></td><td><p><span></span> <span>indinavir</span> <span>possibly increases plasma concentration of</span> <span>tadalafil</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>avoidance of concomitant </span><span>indinavir</span> <span>in severe renal and hepatic impairment advised by manufacturer of</span> <span>telithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int850-tolterodine.htm">Tolterodine</a></td><td><p><span>avoidance of </span><span>indinavir</span> <span>advised by manufacturer of</span> <span>tolterodine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int967-vardenafil.htm">Vardenafil</a></td><td class="cAI"><p><span></span> <span>indinavir</span> <span>increases plasma concentration of</span> <span>vardenafil</span><span>—avoid concomitant use</span></p></td><td></td></tr></tbody></table><p><strong>Lamivudine</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int998-emtricitabine.htm">Emtricitabine</a></td><td><p><span>avoidance of </span><span>lamivudine</span> <span>advised by manufacturer of</span> <span>emtricitabine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int217-trimethoprim.htm">Trimethoprim</a></td><td><p><span>plasma concentration of </span><span>lamivudine</span> <span>increased by</span> <span>trimethoprim</span> <span>(as co-trimoxazole)—avoid concomitant use of high-dose co-trimoxazole</span></p></td><td></td></tr></tbody></table><p><strong>Lopinavir</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as <em>Kaletra</em>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1217-apixaban.htm">Apixaban</a></td><td><p><span>avoidance of </span><span>lopinavir</span> <span>advised by manufacturer of</span> <span>apixaban</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>lopinavir</span> <span>possibly inhibits metabolism of</span> <span>aripiprazole</span> <span>(reduce dose of <span>aripiprazole</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td><p><span>caution with </span><span>lopinavir</span> <span>advised by manufacturer of</span> <span>artemether with lumefantrine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td><p><span>possible increased risk of myopathy when </span><span>lopinavir</span> <span>given with</span> <span>atorvastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>manufacturers advise avoid concomitant use of </span><span>lopinavir</span> <span>with</span> <span>boceprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span><span>lopinavir</span> <span>possibly reduced by</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int315-chlorphenamine.htm">Chlorphenamine</a></td><td><p><span></span> <span>lopinavir</span> <span>possibly increases plasma concentration of</span> <span>chlorphenamine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1076-darifenacin.htm">Darifenacin</a></td><td><p><span>avoidance of </span><span>lopinavir</span> <span>advised by manufacturer of</span> <span>darifenacin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td class="cAI"><p><span></span> <span>lopinavir</span> <span>reduces plasma concentration of</span> <span>darunavir</span><span>, also plasma concentration of <span>lopinavir</span> increased (avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int490-dexamethasone.htm">Dexamethasone</a></td><td><p><span>plasma concentration of </span><span>lopinavir</span> <span>possibly reduced by</span> <span>dexamethasone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td class="cAI"><p><span>plasma concentration of </span><span>lopinavir</span> <span>reduced by</span> <span>efavirenz</span><span>—consider increasing dose of <span>lopinavir</span></span></p></td><td></td></tr><tr><td><a href="bnf_int1177-eltrombopag.htm">Eltrombopag</a></td><td><p><span></span> <span>lopinavir</span> <span>possibly reduces plasma concentration of</span> <span>eltrombopag</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int120-flecainide.htm">Flecainide</a></td><td class="cAI"><p><span></span> <span>lopinavir</span> <span>possibly increases plasma concentration of</span> <span>flecainide</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td><p><span></span> <span>lopinavir</span> <span>reduces plasma concentration of</span> <span>fosamprenavir</span><span>, effect on <span>lopinavir</span> plasma concentration not predictable—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int55-lidocaine.htm">Lidocaine</a></td><td><p><span></span> <span>lopinavir</span> <span>possibly increases plasma concentration of</span> <span>lidocaine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions less likely when lidocaine used topically</p></div></td></tr><tr><td><a href="bnf_int1107-maraviroc.htm">Maraviroc</a></td><td class="cAI"><p><span></span> <span>lopinavir</span> <span>increases plasma concentration of</span> <span>maraviroc</span> <span>(consider reducing dose of <span>maraviroc</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td class="cAI"><p><span>plasma concentration of </span><span>lopinavir</span> <span>possibly reduced by</span> <span>nevirapine</span><span>—consider increasing dose of <span>lopinavir</span></span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span>plasma concentration of </span><span>lopinavir</span> <span>possibly reduced by</span> <span>phenobarbital</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span><span>lopinavir</span> <span>possibly reduced by</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td class="cAI"><p><span></span> <span>lopinavir</span> <span>possibly increases plasma concentration of</span> <span>quetiapine</span><span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td class="cAI"><p><span></span> <span>lopinavir</span> <span>possibly increases plasma concentration of</span> <span>ranolazine</span><span>—manufacturer of <span>ranolazine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>lopinavir</span> <span>reduced by</span> <span>rifampicin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1136-rivaroxaban.htm">Rivaroxaban</a></td><td><p><span>manufacturers advise avoid concomitant use of </span><span>lopinavir</span> <span>with</span> <span>rivaroxaban</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int974-rosuvastatin.htm">Rosuvastatin</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>lopinavir</span> <span>given with</span> <span>rosuvastatin</span><span>—manufacturer of <span>rosuvastatin</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1231-ruxolitinib.htm">Ruxolitinib</a></td><td class="cAI"><p><span>manufacturer of <span>ruxolitinib</span> advises dose reduction when </span><span>lopinavir</span> <span>given with</span> <span>ruxolitinib</span><span>—consult <span>ruxolitinib</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int727-salmeterol.htm">Salmeterol</a></td><td><p><span>manufacturer of </span><span>lopinavir</span> <span>advises avoid concomitant use with</span> <span>salmeterol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>lopinavir</span> <span>given with</span> <span>saquinavir</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>lopinavir</span> <span>given with</span> <span>simvastatin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td><p><span></span> <span>lopinavir</span> <span>possibly increases plasma concentration of</span> <span>sirolimus</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span><span>lopinavir</span> <span>reduced by</span> <span>St John's wort</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>manufacturers advise avoid concomitant use of </span><span>lopinavir</span> <span>with</span> <span>telaprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>avoidance of concomitant </span><span>lopinavir</span> <span>in severe renal and hepatic impairment advised by manufacturer of</span> <span>telithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int954-tenofovir.htm">Tenofovir</a></td><td><p><span></span> <span>lopinavir</span> <span>increases plasma concentration of</span> <span>tenofovir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>lopinavir</span> <span>reduced by</span> <span>tipranavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int850-tolterodine.htm">Tolterodine</a></td><td><p><span>avoidance of </span><span>lopinavir</span> <span>advised by manufacturer of</span> <span>tolterodine</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Nevirapine</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>nevirapine</span> <span>possibly reduces plasma concentration of</span> <span>aripiprazole</span><span>—increase dose of <span>aripiprazole</span></span></p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span></span> <span>nevirapine</span> <span>possibly reduces plasma concentration of</span> <span>atazanavir</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span><span>nevirapine</span> <span>reduced by</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int947-caspofungin.htm">Caspofungin</a></td><td><p><span></span> <span>nevirapine</span> <span>possibly reduces plasma concentration of</span> <span>caspofungin</span><span>—consider increasing dose of <span>caspofungin</span></span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td><p><span></span> <span>nevirapine</span> <span>reduces plasma concentration of</span> <span>clarithromycin</span> <span>(but concentration of an active metabolite increased), also plasma concentration of <span>nevirapine</span> increased</span></p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td><p><span></span> <span>nevirapine</span> <span>reduces plasma concentration of</span> <span>efavirenz</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1135-etravirine.htm">Etravirine</a></td><td class="cAI"><p><span></span> <span>nevirapine</span> <span>possibly reduces plasma concentration of</span> <span>etravirine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>nevirapine</span> <span>increased by</span> <span>fluconazole</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td><p><span></span> <span>nevirapine</span> <span>possibly reduces plasma concentration of</span> <span>fosamprenavir</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td><p><span></span> <span>nevirapine</span> <span>reduces plasma concentration of</span> <span>indinavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span></span> <span>nevirapine</span> <span>possibly reduces plasma concentration of</span> <span>itraconazole</span><span>—consider increasing dose of <span>itraconazole</span></span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span></span> <span>nevirapine</span> <span>reduces plasma concentration of</span> <span>ketoconazole</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td class="cAI"><p><span></span> <span>nevirapine</span> <span>possibly reduces plasma concentration of</span> <span>lopinavir</span><span>—consider increasing dose of <span>lopinavir</span></span></p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as <em>Kaletra</em>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>nevirapine</span> <span>possibly reduces plasma concentration of</span> <span>methadone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td class="cAI"><p><span></span> <span>nevirapine</span> <span>accelerates metabolism of</span> <span>oestrogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td class="cAI"><p><span></span> <span>nevirapine</span> <span>accelerates metabolism of</span> <span>progestogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td><p><span></span> <span>nevirapine</span> <span>possibly increases plasma concentration of</span> <span>rifabutin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>nevirapine</span> <span>reduced by</span> <span>rifampicin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span><span>nevirapine</span> <span>reduced by</span> <span>St John's wort</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td class="cAI"><p><span></span> <span>nevirapine</span> <span>may enhance or reduce anticoagulant effect of</span> <span>warfarin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Ritonavir</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int86-alfentanil.htm">Alfentanil</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>alfentanil</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int30-alfuzosin.htm">Alfuzosin</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>alfuzosin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int406-alprazolam.htm">Alprazolam</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>alprazolam</span> <span>(risk of extreme sedation and respiratory depression—avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>amiodarone</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int232-antidepressants-ssri.htm">Antidepressants, SSRI</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>SSRIs</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>tricyclics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int304-antihistamines-non-sedating.htm">Antihistamines, Non-sedating</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>non-sedating antihistamines</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>antipsychotics</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int404-anxiolytics-and-hypnotics.htm">Anxiolytics and Hypnotics</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>anxiolytics and hypnotics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1217-apixaban.htm">Apixaban</a></td><td><p><span>avoidance of </span><span>ritonavir</span> <span>advised by manufacturer of</span> <span>apixaban</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1010-aprepitant.htm">Aprepitant</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>aprepitant</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly inhibits metabolism of</span> <span>aripiprazole</span> <span>(reduce dose of <span>aripiprazole</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td><p><span>caution with </span><span>ritonavir</span> <span>advised by manufacturer of</span> <span>artemether with lumefantrine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td><p><span>possible increased risk of myopathy when </span><span>ritonavir</span> <span>given with</span> <span>atorvastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1235-axitinib.htm">Axitinib</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>axitinib</span> <span>(reduce dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int167-azithromycin.htm">Azithromycin</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>azithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>plasma concentration of both drugs reduced when </span><span>ritonavir</span> <span>given with</span> <span>boceprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int943-bosentan.htm">Bosentan</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>bosentan</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int496-budesonide.htm">Budesonide</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>budesonide</span> <span>(including <em>inhaled</em>, <em>intranasal</em>, and <em>rectal</em><span>budesonide</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int87-buprenorphine.htm">Buprenorphine</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>buprenorphine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int896-bupropion.htm">Bupropion</a></td><td><p><span></span> <span>ritonavir</span> <span>reduces plasma concentration of</span> <span>bupropion</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int427-buspirone.htm">Buspirone</a></td><td><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>buspirone</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int1204-cabazitaxel.htm">Cabazitaxel</a></td><td class="cAI"><p><span>avoidance of </span><span>ritonavir</span> <span>advised by manufacturer of</span> <span>cabazitaxel</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int466-calcium-channel-blockers.htm">Calcium-channel Blockers</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>calcium-channel blockers</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>clarithromycin</span> <span>(reduce dose of <span>clarithromycin</span> in renal impairment)</span></p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span>manufacturer of </span><span>ritonavir</span> <span>advises avoid concomitant use with</span> <span>clozapine</span> <span>(increased risk of toxicity)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int483-colchicine.htm">Colchicine</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases risk of</span> <span>colchicine</span> <span>toxicity—suspend or reduce dose of <span>colchicine</span> (avoid concomitant use in hepatic or renal impairment)</span></p></td><td></td></tr><tr><td><a href="bnf_int484-corticosteroids.htm">Corticosteroids</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>corticosteroids</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly enhances anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int1240-crizotinib.htm">Crizotinib</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>crizotinib</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1076-darifenacin.htm">Darifenacin</a></td><td><p><span>avoidance of </span><span>ritonavir</span> <span>advised by manufacturer of</span> <span>darifenacin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int490-dexamethasone.htm">Dexamethasone</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>dexamethasone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int714-dexamfetamine.htm">Dexamfetamine</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>dexamfetamine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int90-dextropropoxyphene.htm">Dextropropoxyphene</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>dextropropoxyphene</span> <span>(risk of toxicity)—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int412-diazepam.htm">Diazepam</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>diazepam</span> <span>(risk of extreme sedation and respiratory depression—avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>digoxin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>disopyramide</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int516-docetaxel.htm">Docetaxel</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>docetaxel</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span>avoidance of </span><span>ritonavir</span> <span>advised by manufacturer of</span> <span>dronedarone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td><p><span></span> <span>ritonavir</span> <span>increases toxicity of</span> <span>efavirenz</span><span>, monitor liver function tests</span></p></td><td></td></tr><tr><td><a href="bnf_int963-eletriptan.htm">Eletriptan</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>eletriptan</span> <span>(risk of toxicity)—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1025-eplerenone.htm">Eplerenone</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>eplerenone</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int563-ergotamine-and-methysergide.htm">Ergotamine and Methysergide</a></td><td class="cAI"><p><span>increased risk of ergotism when </span><span>ritonavir</span> <span>given with</span> <span>ergotamine and methysergide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>erythromycin</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int1169-everolimus.htm">Everolimus</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>everolimus</span><span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int95-fentanyl.htm">Fentanyl</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>fentanyl</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1119-fesoterodine.htm">Fesoterodine</a></td><td><p><span>manufacturer of <span>fesoterodine</span> advises dose reduction when </span><span>ritonavir</span> <span>given with</span> <span>fesoterodine</span><span>—consult <span>fesoterodine</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int120-flecainide.htm">Flecainide</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>flecainide</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td><p><span>plasma concentration of </span><span>ritonavir</span> <span>increased by</span> <span>fluconazole</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int416-flurazepam.htm">Flurazepam</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>flurazepam</span> <span>(risk of extreme sedation and respiratory depression—avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int497-fluticasone.htm">Fluticasone</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of <em>inhaled</em> and <em>intranasal</em></span> <span>fluticasone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int163-fusidic-acid.htm">Fusidic Acid</a></td><td class="cAI"><p><span>plasma concentration of both drugs increased when </span><span>ritonavir</span> <span>given with</span> <span>fusidic acid</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>indinavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>combination of </span><span>ritonavir</span> <span>with</span> <span>itraconazole</span> <span>may increase plasma concentration of either drug (or both)</span></p></td><td></td></tr><tr><td><a href="bnf_int1050-ivabradine.htm">Ivabradine</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>ivabradine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>combination of </span><span>ritonavir</span> <span>with</span> <span>ketoconazole</span> <span>may increase plasma concentration of either drug (or both)</span></p></td><td></td></tr><tr><td><a href="bnf_int283-lamotrigine.htm">Lamotrigine</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly reduces plasma concentration of</span> <span>lamotrigine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td class="cAI"><p><span>avoidance of </span><span>ritonavir</span> <span>advised by manufacturer of</span> <span>lapatinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int846-lercanidipine.htm">Lercanidipine</a></td><td><p><span>avoidance of </span><span>ritonavir</span> <span>advised by manufacturer of</span> <span>lercanidipine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1107-maraviroc.htm">Maraviroc</a></td><td><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>maraviroc</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>ritonavir</span> <span>reduces plasma concentration of</span> <span>methadone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>midazolam</span> <span>(risk of prolonged sedation—avoid concomitant use of <em>oral</em><span>midazolam</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int98-morphine.htm">Morphine</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly reduces plasma concentration of</span> <span>morphine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int60-nsaids.htm">NSAIDs</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>NSAIDs</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> <em>See also </em>Aspirin. Interactions do not generally apply to topical NSAIDs
</p></div></td></tr><tr><td><a href="bnf_int1118-nilotinib.htm">Nilotinib</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>nilotinib</span><span>—manufacturer of <span>nilotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>accelerates metabolism of</span> <span>oestrogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int366-olanzapine.htm">Olanzapine</a></td><td><p><span></span> <span>ritonavir</span> <span>reduces plasma concentration of</span> <span>olanzapine</span><span>—consider increasing dose of <span>olanzapine</span></span></p></td><td></td></tr><tr><td><a href="bnf_int517-paclitaxel.htm">Paclitaxel</a></td><td><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>paclitaxel</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int236-paroxetine.htm">Paroxetine</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly reduces plasma concentration of</span> <span>paroxetine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1186-pazopanib.htm">Pazopanib</a></td><td class="cAI"><p><span>avoidance of </span><span>ritonavir</span> <span>advised by manufacturer of</span> <span>pazopanib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int102-pethidine.htm">Pethidine</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>reduces plasma concentration of</span> <span>pethidine</span><span>, but increases plasma concentration of toxic metabolite of <span>pethidine</span> (avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int223-phenindione.htm">Phenindione</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly enhances anticoagulant effect of</span> <span>phenindione</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </p></div></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span><span>ritonavir</span> <span>possibly reduced by</span> <span>phenytoin</span><span>, also plasma concentration of <span>phenytoin</span> possibly affected</span></p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>pimozide</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int78-piroxicam.htm">Piroxicam</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>piroxicam</span> <span>(risk of toxicity)—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int486-prednisolone.htm">Prednisolone</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>prednisolone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int125-propafenone.htm">Propafenone</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>propafenone</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>quetiapine</span><span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int341-quinine.htm">Quinine</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>quinine</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>ranolazine</span><span>—manufacturer of <span>ranolazine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>rifabutin</span> <span>(increased risk of toxicity—reduce <span>rifabutin</span> dose)</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span><span>ritonavir</span> <span>possibly reduced by</span> <span>rifampicin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1136-rivaroxaban.htm">Rivaroxaban</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>rivaroxaban</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int974-rosuvastatin.htm">Rosuvastatin</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>ritonavir</span> <span>given with</span> <span>rosuvastatin</span><span>—manufacturer of <span>rosuvastatin</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1231-ruxolitinib.htm">Ruxolitinib</a></td><td class="cAI"><p><span>manufacturer of <span>ruxolitinib</span> advises dose reduction when </span><span>ritonavir</span> <span>given with</span> <span>ruxolitinib</span><span>—consult <span>ruxolitinib</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int727-salmeterol.htm">Salmeterol</a></td><td><p><span>manufacturer of </span><span>ritonavir</span> <span>advises avoid concomitant use with</span> <span>salmeterol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>saquinavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int858-sildenafil.htm">Sildenafil</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>significantly increases plasma concentration of</span> <span>sildenafil</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>ritonavir</span> <span>given with</span> <span>simvastatin</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int1020-solifenacin.htm">Solifenacin</a></td><td><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>solifenacin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span><span>ritonavir</span> <span>reduced by</span> <span>St John's wort</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>tacrolimus</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int945-tadalafil.htm">Tadalafil</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>tadalafil</span><span>—manufacturer of <span>tadalafil</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly reduces plasma concentration of</span> <span>telaprevir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>avoidance of concomitant </span><span>ritonavir</span> <span>in severe renal and hepatic impairment advised by manufacturer of</span> <span>telithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>accelerates metabolism of</span> <span>theophylline</span> <span>(reduced plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>ticagrelor</span><span>—manufacturer of <span>ticagrelor</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int275-tolbutamide.htm">Tolbutamide</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>tolbutamide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int850-tolterodine.htm">Tolterodine</a></td><td><p><span>avoidance of </span><span>ritonavir</span> <span>advised by manufacturer of</span> <span>tolterodine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int255-trazodone.htm">Trazodone</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>trazodone</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int1163-ulipristal.htm">Ulipristal</a></td><td class="cAI"><p><span>avoidance of </span><span>ritonavir</span> <span>advised by manufacturer of</span> <span>ulipristal</span> <span>(contraceptive effect of <span>ulipristal</span> possibly reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly reduces plasma concentration of</span> <span>valproate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int967-vardenafil.htm">Vardenafil</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>increases plasma concentration of</span> <span>vardenafil</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1002-vinblastine.htm">Vinblastine</a></td><td><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>vinblastine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1181-vinflunine.htm">Vinflunine</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>vinflunine</span><span>—manufacturer of <span>vinflunine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>reduces plasma concentration of</span> <span>voriconazole</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>may enhance or reduce anticoagulant effect of</span> <span>warfarin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int425-zolpidem.htm">Zolpidem</a></td><td class="cAI"><p><span></span> <span>ritonavir</span> <span>possibly increases plasma concentration of</span> <span>zolpidem</span> <span>(risk of extreme sedation and respiratory depression—avoid concomitant use)</span></p></td><td></td></tr></tbody></table><p><strong>Saquinavir</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int86-alfentanil.htm">Alfentanil</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>alfentanil</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>amiodarone</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>tricyclics</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int293-antifungals-imidazole.htm">Antifungals, Imidazole</a></td><td><p><span>plasma concentration of </span><span>saquinavir</span> <span>possibly increased by</span> <span>imidazoles</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int300-antifungals-triazole.htm">Antifungals, Triazole</a></td><td><p><span>plasma concentration of </span><span>saquinavir</span> <span>possibly increased by</span> <span>triazoles</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1217-apixaban.htm">Apixaban</a></td><td><p><span>avoidance of </span><span>saquinavir</span> <span>advised by manufacturer of</span> <span>apixaban</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>saquinavir</span> <span>possibly inhibits metabolism of</span> <span>aripiprazole</span> <span>(reduce dose of <span>aripiprazole</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td><p><span>caution with </span><span>saquinavir</span> <span>advised by manufacturer of</span> <span>artemether with lumefantrine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>atazanavir</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td><p><span>possible increased risk of myopathy when </span><span>saquinavir</span> <span>given with</span> <span>atorvastatin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1235-axitinib.htm">Axitinib</a></td><td><p><span></span> <span>saquinavir</span> <span>possibly increases plasma concentration of</span> <span>axitinib</span> <span>(reduce dose of <span>axitinib</span>—consult <span>axitinib</span> product literature)</span></p></td><td></td></tr><tr><td><a href="bnf_int1204-cabazitaxel.htm">Cabazitaxel</a></td><td class="cAI"><p><span>avoidance of </span><span>saquinavir</span> <span>advised by manufacturer of</span> <span>cabazitaxel</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span><span>saquinavir</span> <span>possibly reduced by</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>plasma concentration of both drugs increased when </span><span>saquinavir</span> <span>given with</span> <span>ciclosporin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>plasma concentration of </span><span>saquinavir</span> <span>possibly increased by</span> <span>cimetidine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>clarithromycin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>clozapine</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int1240-crizotinib.htm">Crizotinib</a></td><td class="cAI"><p><span></span> <span>saquinavir</span> <span>possibly increases plasma concentration of</span> <span>crizotinib</span><span>—manufacturer of <span>crizotinib</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int161-dapsone.htm">Dapsone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>dapsone</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1076-darifenacin.htm">Darifenacin</a></td><td><p><span>avoidance of </span><span>saquinavir</span> <span>advised by manufacturer of</span> <span>darifenacin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td><p><span></span> <span>saquinavir</span> <span>reduces plasma concentration of</span> <span>darunavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int490-dexamethasone.htm">Dexamethasone</a></td><td><p><span>plasma concentration of </span><span>saquinavir</span> <span>possibly reduced by</span> <span>dexamethasone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>disopyramide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>dronedarone</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td><p><span>plasma concentration of </span><span>saquinavir</span> <span>significantly reduced by</span> <span>efavirenz</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1025-eplerenone.htm">Eplerenone</a></td><td><p><span></span> <span>saquinavir</span> <span>increases plasma concentration of</span> <span>eplerenone</span> <span>(reduce dose of <span>eplerenone</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int563-ergotamine-and-methysergide.htm">Ergotamine and Methysergide</a></td><td class="cAI"><p><span>increased risk of ergotism when </span><span>saquinavir</span> <span>given with</span> <span>ergotamine and methysergide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>erythromycin</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int914-esomeprazole.htm">Esomeprazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>saquinavir</span> <span>possibly increased by</span> <span>esomeprazole</span><span>—manufacturer of <span>saquinavir</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1169-everolimus.htm">Everolimus</a></td><td class="cAI"><p><span></span> <span>saquinavir</span> <span>possibly increases plasma concentration of</span> <span>everolimus</span><span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int95-fentanyl.htm">Fentanyl</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>fentanyl</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1119-fesoterodine.htm">Fesoterodine</a></td><td><p><span>manufacturer of <span>fesoterodine</span> advises dose reduction when </span><span>saquinavir</span> <span>given with</span> <span>fesoterodine</span><span>—consult <span>fesoterodine</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int120-flecainide.htm">Flecainide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>flecainide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int163-fusidic-acid.htm">Fusidic Acid</a></td><td class="cAI"><p><span>plasma concentration of both drugs increased when </span><span>saquinavir</span> <span>given with</span> <span>fusidic acid</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>haloperidol</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td><p><span>plasma concentration of </span><span>saquinavir</span> <span>increased by</span> <span>indinavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td><p><span>plasma concentration of </span><span>saquinavir</span> <span>increased by</span> <span>ketoconazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int753-lansoprazole.htm">Lansoprazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>saquinavir</span> <span>possibly increased by</span> <span>lansoprazole</span><span>—manufacturer of <span>saquinavir</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td class="cAI"><p><span>avoidance of </span><span>saquinavir</span> <span>advised by manufacturer of</span> <span>lapatinib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int55-lidocaine.htm">Lidocaine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>lidocaine</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions less likely when lidocaine used topically</p></div></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>lopinavir</span><span>—avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as <em>Kaletra</em>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int1107-maraviroc.htm">Maraviroc</a></td><td class="cAI"><p><span></span> <span>saquinavir</span> <span>increases plasma concentration of</span> <span>maraviroc</span> <span>(consider reducing dose of <span>maraviroc</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>methadone</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td class="cAI"><p><span></span> <span>saquinavir</span> <span>increases plasma concentration of</span> <span>midazolam</span> <span>(risk of prolonged sedation—avoid concomitant use of <em>oral</em><span>midazolam</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int841-mizolastine.htm">Mizolastine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>mizolastine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int973-moxifloxacin.htm">Moxifloxacin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>moxifloxacin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int752-omeprazole.htm">Omeprazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>saquinavir</span> <span>increased by</span> <span>omeprazole</span><span>—manufacturer of <span>saquinavir</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int754-pantoprazole.htm">Pantoprazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>saquinavir</span> <span>possibly increased by</span> <span>pantoprazole</span><span>—manufacturer of <span>saquinavir</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1186-pazopanib.htm">Pazopanib</a></td><td class="cAI"><p><span>avoidance of </span><span>saquinavir</span> <span>advised by manufacturer of</span> <span>pazopanib</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int808-pentamidine-isetionate.htm">Pentamidine Isetionate</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>pentamidine isetionate</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span>plasma concentration of </span><span>saquinavir</span> <span>possibly reduced by</span> <span>phenobarbital</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int373-phenothiazines.htm">Phenothiazines</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>phenothiazines</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span><span>saquinavir</span> <span>possibly reduced by</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span></span> <span>saquinavir</span> <span>possibly increases plasma concentration of</span> <span>pimozide</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int1237-piperaquine-with-artenimol.htm">Piperaquine with Artenimol</a></td><td class="cAI"><p><span>avoidance of </span><span>saquinavir</span> <span>advised by manufacturer of</span> <span>piperaquine with artenimol</span> <span>(possible risk of ventricular arrhythmias)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Piperaquine has a long half-life; there is a potential for drug interactions to occur for up to 3 months after treatment has been stopped</p></div></td></tr><tr><td><a href="bnf_int125-propafenone.htm">Propafenone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>propafenone</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td class="cAI"><p><span></span> <span>saquinavir</span> <span>possibly increases plasma concentration of</span> <span>quetiapine</span><span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int341-quinine.htm">Quinine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>quinine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int869-rabeprazole.htm">Rabeprazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>saquinavir</span> <span>possibly increased by</span> <span>rabeprazole</span><span>—manufacturer of <span>saquinavir</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td class="cAI"><p><span></span> <span>saquinavir</span> <span>possibly increases plasma concentration of</span> <span>ranolazine</span><span>—manufacturer of <span>ranolazine</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span></span> <span>saquinavir</span> <span>increases plasma concentration of</span> <span>rifabutin</span> <span>(also plasma concentration of <span>saquinavir</span> reduced)</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span><span>saquinavir</span> <span>significantly reduced by</span> <span>rifampicin</span><span>, also risk of hepatotoxicity—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>saquinavir</span> <span>increased by</span> <span>ritonavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1136-rivaroxaban.htm">Rivaroxaban</a></td><td><p><span>avoidance of </span><span>saquinavir</span> <span>advised by manufacturer of</span> <span>rivaroxaban</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int974-rosuvastatin.htm">Rosuvastatin</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span><span>saquinavir</span> <span>given with</span> <span>rosuvastatin</span><span>—manufacturer of <span>rosuvastatin</span> advises avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int1231-ruxolitinib.htm">Ruxolitinib</a></td><td class="cAI"><p><span>manufacturer of <span>ruxolitinib</span> advises dose reduction when </span><span>saquinavir</span> <span>given with</span> <span>ruxolitinib</span><span>—consult <span>ruxolitinib</span> product literature</span></p></td><td></td></tr><tr><td><a href="bnf_int858-sildenafil.htm">Sildenafil</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>sildenafil</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span><span>saquinavir</span> <span>given with</span> <span>simvastatin</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int455-sotalol.htm">Sotalol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>sotalol</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span><span>saquinavir</span> <span>reduced by</span> <span>St John's wort</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>saquinavir</span> <span>increases plasma concentration of</span> <span>tacrolimus</span> <span>(consider reducing dose of <span>tacrolimus</span>)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int945-tadalafil.htm">Tadalafil</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>tadalafil</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>avoidance of </span><span>saquinavir</span> <span>advised by manufacturer of</span> <span>telithromycin</span> <span>(risk of ventricular arrhythmias)</span></p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>saquinavir</span> <span>reduced by</span> <span>tipranavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int850-tolterodine.htm">Tolterodine</a></td><td><p><span>avoidance of </span><span>saquinavir</span> <span>advised by manufacturer of</span> <span>tolterodine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int255-trazodone.htm">Trazodone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>trazodone</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int967-vardenafil.htm">Vardenafil</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span><span>saquinavir</span> <span>given with</span> <span>vardenafil</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td><p><span></span> <span>saquinavir</span> <span>possibly enhances anticoagulant effect of</span> <span>warfarin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Stavudine</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int397-didanosine.htm">Didanosine</a></td><td class="cAI"><p><span>increased risk of side-effects when </span><span>stavudine</span> <span>given with</span> <span>didanosine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Antacids in tablet formulation may affect absorption of other drugs</p></div></td></tr><tr><td><a href="bnf_int506-doxorubicin.htm">Doxorubicin</a></td><td><p><span>effects of </span><span>stavudine</span> <span>possibly inhibited by</span> <span>doxorubicin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1052-hydroxycarbamide.htm">Hydroxycarbamide</a></td><td class="cAI"><p><span>increased risk of toxicity when </span><span>stavudine</span> <span>given with</span> <span>hydroxycarbamide</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int953-ribavirin.htm">Ribavirin</a></td><td class="cAI"><p><span>increased risk of toxicity when </span><span>stavudine</span> <span>given with</span> <span>ribavirin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int403-zidovudine.htm">Zidovudine</a></td><td class="cAI"><p><span>effects of </span><span>stavudine</span> <span>possibly inhibited by</span> <span>zidovudine</span> <span>(manufacturers advise avoid concomitant use)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</p></div></td></tr></tbody></table><p><strong>Zidovudine</strong> belongs to <strong>Antivirals</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int431-atovaquone.htm">Atovaquone</a></td><td><p><span>plasma concentration of </span><span>zidovudine</span> <span>increased by</span> <span>atovaquone</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td><p><span>absorption of </span><span>zidovudine</span> <span>reduced by</span> <span>clarithromycin</span> <span>tablets (give at least 2 hours apart)</span></p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td class="cAI"><p><span>plasma concentration of </span><span>zidovudine</span> <span>increased by</span> <span>fluconazole</span> <span>(increased risk of toxicity)</span></p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int395-ganciclovir.htm">Ganciclovir</a></td><td class="cAI"><p><span>profound myelosuppression when </span><span>zidovudine</span> <span>given with</span> <span>ganciclovir</span> <span>(if possible avoid concomitant administration, particularly during initial <span>ganciclovir</span> therapy)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of myelosuppression with other myelosuppressive drugs—consult product literature</p></div></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span>plasma concentration of </span><span>zidovudine</span> <span>possibly increased by</span> <span>methadone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int60-nsaids.htm">NSAIDs</a></td><td><p><span>increased risk of haematological toxicity when </span><span>zidovudine</span> <span>given with</span> <span>NSAIDs</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> <em>See also </em>Aspirin. Interactions do not generally apply to topical NSAIDs
</p></div></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span></span> <span>zidovudine</span> <span>increases or decreases plasma concentration of</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int663-probenecid.htm">Probenecid</a></td><td class="cAI"><p><span>excretion of </span><span>zidovudine</span> <span>reduced by</span> <span>probenecid</span> <span>(increased plasma concentration and risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int340-pyrimethamine.htm">Pyrimethamine</a></td><td><p><span>increased antifolate effect when </span><span>zidovudine</span> <span>given with</span> <span>pyrimethamine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int953-ribavirin.htm">Ribavirin</a></td><td class="cAI"><p><span>increased risk of anaemia when </span><span>zidovudine</span> <span>given with</span> <span>ribavirin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>manufacturer of </span><span>zidovudine</span> <span>advises avoid concomitant use with</span> <span>rifampicin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int401-stavudine.htm">Stavudine</a></td><td class="cAI"><p><span></span> <span>zidovudine</span> <span>possibly inhibits effects of</span> <span>stavudine</span> <span>(manufacturers advise avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>zidovudine</span> <span>reduced by</span> <span>tipranavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td><p><span>plasma concentration of </span><span>zidovudine</span> <span>possibly increased by</span> <span>valproate</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr></tbody></table></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="bnf_int1225-rilpivirine.htm" title="Rilpivirine">Rilpivirine</a></li><li><a href="bnf_int1216-telaprevir.htm" title="Telaprevir">Telaprevir</a></li><li><a href="bnf_int1214-boceprevir.htm" title="Boceprevir">Boceprevir</a></li><li><a href="bnf_int1135-etravirine.htm" title="Etravirine">Etravirine</a></li><li><a href="bnf_int1019-fosamprenavir.htm" title="Fosamprenavir">Fosamprenavir</a></li><li><a href="bnf_int1112-telbivudine.htm" title="Telbivudine">Telbivudine</a></li><li><a href="bnf_int1111-raltegravir.htm" title="Raltegravir">Raltegravir</a></li><li><a href="bnf_int1107-maraviroc.htm" title="Maraviroc">Maraviroc</a></li><li><a href="bnf_int1091-darunavir.htm" title="Darunavir">Darunavir</a></li><li><a href="bnf_int1088-adefovir.htm" title="Adefovir">Adefovir</a></li><li><a href="bnf_int1055-tipranavir.htm" title="Tipranavir">Tipranavir</a></li><li><a href="bnf_int1005-atazanavir.htm" title="Atazanavir">Atazanavir</a></li><li><a href="bnf_int998-emtricitabine.htm" title="Emtricitabine">Emtricitabine</a></li><li><a href="bnf_int954-tenofovir.htm" title="Tenofovir">Tenofovir</a></li><li><a href="bnf_int953-ribavirin.htm" title="Ribavirin">Ribavirin</a></li><li><a href="bnf_int952-foscarnet.htm" title="Foscarnet">Foscarnet</a></li><li><a href="bnf_int951-cidofovir.htm" title="Cidofovir">Cidofovir</a></li><li><a href="bnf_int907-abacavir.htm" title="Abacavir">Abacavir</a></li><li id="_bnf_int392-aciclovir"><a href="bnf_int392-aciclovir.htm" title="Aciclovir">Aciclovir</a></li><li><a href="bnf_int397-didanosine.htm" title="Didanosine">Didanosine</a></li><li><a href="bnf_int874-efavirenz.htm" title="Efavirenz">Efavirenz</a></li><li><a href="bnf_int393-famciclovir.htm" title="Famciclovir">Famciclovir</a></li><li id="_bnf_int395-ganciclovir"><a href="bnf_int395-ganciclovir.htm" title="Ganciclovir">Ganciclovir</a></li><li><a href="bnf_int398-indinavir.htm" title="Indinavir">Indinavir</a></li><li><a href="bnf_int399-lamivudine.htm" title="Lamivudine">Lamivudine</a></li><li><a href="bnf_int922-lopinavir.htm" title="Lopinavir">Lopinavir</a></li><li><a href="bnf_int843-nevirapine.htm" title="Nevirapine">Nevirapine</a></li><li><a href="bnf_int400-ritonavir.htm" title="Ritonavir">Ritonavir</a></li><li><a href="bnf_int791-saquinavir.htm" title="Saquinavir">Saquinavir</a></li><li><a href="bnf_int401-stavudine.htm" title="Stavudine">Stavudine</a></li><li><a href="bnf_int403-zidovudine.htm" title="Zidovudine">Zidovudine</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int390-zuclopenthixol.htm">Previous: Zuclopenthixol</a> | <a class="top" href="bnf_int391-antivirals.htm#">Top</a> | <a accesskey="]" href="bnf_int1225-rilpivirine.htm">Next: Rilpivirine</a> ►</div></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>